WO2014079573A1 - Multi-day patch for the transdermal administration of rotigotine - Google Patents
Multi-day patch for the transdermal administration of rotigotine Download PDFInfo
- Publication number
- WO2014079573A1 WO2014079573A1 PCT/EP2013/003515 EP2013003515W WO2014079573A1 WO 2014079573 A1 WO2014079573 A1 WO 2014079573A1 EP 2013003515 W EP2013003515 W EP 2013003515W WO 2014079573 A1 WO2014079573 A1 WO 2014079573A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rotigotine
- layer
- transdermal therapeutic
- therapeutic system
- self
- Prior art date
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims abstract description 355
- 229960003179 rotigotine Drugs 0.000 title claims abstract description 353
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 179
- 239000000853 adhesive Substances 0.000 claims abstract description 136
- 239000011159 matrix material Substances 0.000 claims abstract description 119
- 239000011248 coating agent Substances 0.000 claims abstract description 95
- 238000000576 coating method Methods 0.000 claims abstract description 95
- 239000002904 solvent Substances 0.000 claims abstract description 83
- 238000002360 preparation method Methods 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000003442 weekly effect Effects 0.000 claims abstract description 13
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 208000005793 Restless legs syndrome Diseases 0.000 claims abstract description 7
- 230000004771 dopaminergic neurodegeneration Effects 0.000 claims abstract description 6
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 5
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 5
- 239000010410 layer Substances 0.000 claims description 298
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 132
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 122
- 239000012790 adhesive layer Substances 0.000 claims description 102
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 92
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 92
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 92
- 239000000203 mixture Substances 0.000 claims description 69
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 60
- 239000013464 silicone adhesive Substances 0.000 claims description 44
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 21
- 229920001296 polysiloxane Polymers 0.000 claims description 19
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 12
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 12
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 9
- 239000002798 polar solvent Substances 0.000 claims description 9
- 239000007858 starting material Substances 0.000 claims description 9
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 8
- 239000003586 protic polar solvent Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 5
- 238000003475 lamination Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 238000004080 punching Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 229940100640 transdermal system Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 208000006829 Allan-Herndon-Dudley syndrome Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 abstract description 42
- 229940079593 drug Drugs 0.000 description 60
- 239000003814 drug Substances 0.000 description 60
- 230000000052 comparative effect Effects 0.000 description 41
- 239000007962 solid dispersion Substances 0.000 description 29
- 230000002354 daily effect Effects 0.000 description 21
- 230000036470 plasma concentration Effects 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000002356 single layer Substances 0.000 description 18
- 239000006185 dispersion Substances 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000002270 dispersing agent Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- -1 polyethylene Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000011888 foil Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000001993 wax Substances 0.000 description 10
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 9
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 9
- 229940001584 sodium metabisulfite Drugs 0.000 description 9
- 235000010262 sodium metabisulphite Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VZWGRQBCURJOMT-UHFFFAOYSA-N Dodecyl acetate Chemical compound CCCCCCCCCCCCOC(C)=O VZWGRQBCURJOMT-UHFFFAOYSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 229920003082 Povidone K 90 Polymers 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000005038 ethylene vinyl acetate Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000007970 homogeneous dispersion Substances 0.000 description 6
- 239000012943 hotmelt Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 6
- 229960000984 tocofersolan Drugs 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- BXOUVIIITJXIKB-UHFFFAOYSA-N ethene;styrene Chemical group C=C.C=CC1=CC=CC=C1 BXOUVIIITJXIKB-UHFFFAOYSA-N 0.000 description 5
- 238000010030 laminating Methods 0.000 description 5
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229940117958 vinyl acetate Drugs 0.000 description 4
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008385 outer phase Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 2
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 description 2
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 229910052909 inorganic silicate Inorganic materials 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 2
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- CCEFMUBVSUDRLG-KXUCPTDWSA-N (4R)-limonene 1,2-epoxide Natural products C1[C@H](C(=C)C)CC[C@@]2(C)O[C@H]21 CCEFMUBVSUDRLG-KXUCPTDWSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- NQFUSWIGRKFAHK-UHFFFAOYSA-N 2,3-epoxypinane Chemical compound CC12OC1CC1C(C)(C)C2C1 NQFUSWIGRKFAHK-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- CCEFMUBVSUDRLG-XNWIYYODSA-N Limonene-1,2-epoxide Chemical compound C1[C@H](C(=C)C)CCC2(C)OC21 CCEFMUBVSUDRLG-XNWIYYODSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 208000012195 Reunion island Larsen syndrome Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
- CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007925 in vitro drug release testing Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940020452 neupro Drugs 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
- 229940065472 octyl acrylate Drugs 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B37/00—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
- B32B37/12—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by using adhesives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2556/00—Patches, e.g. medical patches, repair patches
Abstract
The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent -based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self- adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent -based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.
Description
MULTI-DAY PATCH FOR THE TRANSDERMAL ADMINISTRATION OF
ROTIGOTINE
Description
Field of the Invention
The present invention relates to a novel multi -day transdermal therapeutic system (TTS) , which is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days and up to at least 7 days. Technical background
Rotigotine is the International Non-Proprietary Name (INN) of the compound ( - ) - 5 , 6 , 7 , 8 -tetrahydro-6 - [propyl - [2 - ( 2 - thienyl ) ethyl] -amino] - 1 -naphthalenol having the structure shown below
Rotigotine exists in two different polymorphic states, Polymorphic Form I and Polymorphic Form II, which can be differentiated by their melting point, infrared (IR) spectroscopy, solid state nuclear magnetic resonance (SSNMR) or Raman spectroscopy as well as differential scanning
calorimetry (DSC) and X-ray powder diffraction (XRD) . The different physicochemical characteristics of the two polymorphic forms of rotigotine are for example described in WO 2009/068520.
Rotigotine is a non-ergolinic dopamine D1/D2/D3 -receptor agonist that resembles dopamine structurally and has a similar receptor profile but a higher receptor affinity. In contrast to other non-ergolinic dopamine agonists, rotigotine has significant Dl activity, which may contribute to a greater physiological action.
In contrast to ergolinic compounds, rotigotine has a very low affinity for 5 HT2B receptors and thus a low risk of inducing fibrosis .
Actions on non-dopaminergic receptors (such as 5-ΗΤχΑ agonism and A2B antagonism) may contribute to other beneficial effects, such as ant idyskinetic activity, neuroprotective activity and antidepressive effects.
Rotigotine is disclosed as active agent for treating patients suffering from Parkinson's disease (described in WO 2002/089777) , Parkinson's plus syndrome (described in WO 2005/092331) , depression (described in WO 2005/009424) and the restless-legs syndrome (described in WO 2003/092677) as well as for the treatment or prevention of dopaminergic neuron loss (described in WO 2005/063237) .
Known pharmaceutical compositions containing rotigotine comprise a single-day, solvent-based transdermal therapeutic system (TTS) (described in WO 99/49852) , a depot form
(described in WO 02/15903) , an iontophoret ic device (described in WO 2004/050083) and an intranasal formulation
(described in WO 2005/063236) .
In WO 2004/012721, a transdermal therapeutic system (TTS) is described, which contains rotigotine in a self-adhesive layer being prepared from a hot -meltable adhesive. The transdermal therapeutic systems of WO 2004/012721 are provided for a single-day or a multi-day application and allow for a continuous release of rotigotine for e.g. up to at least 7 days in an in vitro skin permeation model.
Compared to the hot-meltable adhesive-based transdermal therapeutic systems of WO 2004/012721, the solvent -based transdermal therapeutic systems known from the prior art have a limited capacity for loading their self-adhesive layer with rotigotine . So far, it was therefore not possible to prepare solvent- based transdermal therapeutic systems providing for a continuous release of rotigotine for 3 or more days.
It was, therefore, an object of the present invention to provide a solvent-based transdermal therapeutic system comprising rotigotine in an amount allowing for the continuous administration of therapeutically effective amounts of rotigotine for at least 3 days and up to at least 7 days after one application.
Summary of the invention
The present invention is based on the development of solvent - based self-adhesive matrices for transdermal therapeutic systems containing increased amounts of rotigotine, which allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days and up to at least 7 days after one application of a corresponding transdermal therapeutic system and wherein the transdermal therapeutic system complies with the needs of a convenient application in view of size, thickness and skin tolerance and can easily and cost-effectively be prepared.
Moreover, it was surprisingly found that the total amount of rotigotine being required for the continuous administration of therapeutically effective amounts of rotigotine for at least 3 days and up to at least 7 days by the transdermal therapeutic system of the present invention was lower than expected/calculated for the respective number of single-day solvent-based transdermal therapeutic systems known from the prior art .
In a first aspect, the present invention therefore provides a transdermal therapeutic system, comprising
(a) a backing layer,
(b) a solvent -based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer.
In a further embodiment the transdermal therapeutic system, comprising
(a) a backing layer,
(b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
wherein the self-adhesive matrix layer has a coating weight of about 100-400 g/m2 and comprises a reservoir layer
containing about 9-20 wt.-% rotigotine based on the weight of the reservoir layer.
In the context of the present application the term "about" shall mean +/- 10 % of the respective figure unless otherwise indicated.
In one embodiment, the self-adhesive matrix layer of the transdermal therapeutic system further comprises a skin adhesive layer containing rotigotine in a concentration of about 0-10 wt.-% based on the weight of the skin adhesive layer and the skin adhesive layer is provided between the reservoir layer and the release liner and has a lower rotigotine concentration than the reservoir layer.
In a further embodiment, the reservoir layer of the transdermal therapeutic system has a coating weight of about 75-300 g/m2, preferably of about 75-200 g/m2 , more preferably about 100-150 g/m2 and contains about 9-25 wt.-% rotigotine, preferably about 18 wt.-% rotigotine based on the weight of the reservoir layer.
In a further embodiment, the reservoir layer of the transdermal therapeutic system has a coating weight of about 75-200 g/m2, preferably of about 100-150 g/m2 and contains about 9-25 wt.-% rotigotine, preferably about 18 wt.-% rotigotine based on the weight of the reservoir layer and the skin adhesive layer has a coating weight of about 10-150 g/m2.
In a preferred embodiment, the skin adhesive layer of the transdermal therapeutic system has a coating weight of about 15-120 g/m2 and contains about 5-10 wt.-% rotigotine based on the weight of the skin adhesive layer.
In a further preferred embodiment, the skin adhesive layer of the transdermal therapeutic system has a coating weight of about 15-50 g/m2 and contains about 0-5 wt.-% rotigotine based on the weight of the skin adhesive layer.
In a further embodiment, the transdermal system contains about 10-32 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer, preferably about 27 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer.
In a preferred embodiment, the reservoir layer or the reservoir layer and the skin adhesive layer, if it contains rotigotine, of the transdermal therapeutic system further contain (s) polyvinylpyrrolidone and the rotigotine to polyvinylpyrrolidone weight ratio in the respective layer is 9:2 to 9:5, preferably 9:3 to 9:5, or multiples thereof.
In a further preferred embodiment, the reservoir layer and, if present, the skin adhesive layer of the transdermal therapeutic system each contain at least one, preferably two, amine-resistant silicone pressure sensitive adhesive (s) .
In a further embodiment, the transdermal therapeutic system is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3-7 days.
In a preferred embodiment, the transdermal therapeutic system is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days .
The multi-day transdermal therapeutic system of the present invention has the advantage of allowing for a reduced application frequency compared to daily applied conventional transdermal therapeutic systems. This is particularly advantageous for patients suffering from severe dopaminergic disorders, like Parkinson's Disease, as these patients often experience motor disabilities which make the frequent handling and administration of transdermal patches difficult. At the same time, the number of skin application sites to be treated with patches during a long-term patch medication is reduced. A prolongation of the medication interval e.g. from 1 day to at least 3 or even at least 7 days minimizes the potential risk of skin lesions associated with repeated patch stripping from the patients' skin at skin application sites
selected for repeated patch administration. In addition, the influence of inter- and intra- individually differing lag- times on the absorption of rotigotine, which may be associated with the daily replacement of rotigotine- containing patches in the case of low skin permeability and which may cause therapeutically unwanted fluctuations of the plasma levels of rotigotine, can be eliminated by the multi- day patches of the present invention. Finally, the replacement of a daily patch administration by one single administration for several days, for example by an administration once or twice weekly, contributes to the reduction of the costs of the respective medication by saving material and production time. In a second aspect, the present invention provides a kit comprising two transdermal therapeutic systems of the present invention, wherein the two transdermal therapeutic systems may have the same or a different rotigotine content. In one embodiment, the two transdermal therapeutic systems of the kit have a different rotigotine content and one of them is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days and the other one is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 4 days. In a preferred embodiment, the two transdermal therapeutic systems of the kit have the same rotigotine content and each of them is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 4 days .
In a third aspect, the present invention provides a method for the preparation of the transdermal therapeutic system of the present invention.
In present invention the preparation method involves the use of a solvent system consisting of an aprotic polar solvent and a protic polar solvent. In one embodiment, the preparation method involves the use of a solvent system consisting of an aprotic polar solvent and a protic polar solvent in a ratio of 2:1 to 9:1.
In a preferred embodiment, the solvent system consists of a carboxylic acid ester and an aliphatic alcohol . In a more preferred embodiment the solvent system consists of ethyl acetate and ethanol. In a particular preferred embodiment the solvent system consists of ethyl acetate and ethanol in a ratio of 2:1 to 6:1.
In a further embodiment, the preparation method involves the use of a solvent system consisting of heptane and ethanol in a ratio of 1.5:1 to 1:1.5.
In another preferred embodiment, the preparation method is carried out at room temperature and rotigotine is added to the solvent system in two portions. When rotigotine is added in two portions, one portion is added before and the other portion is added after polyvinylpyrrolidone is added. In another preferred embodiment, the preparation method is carried out at room temperature and the total amount of rotigotine is added to the solvent system in one portion together with polyvinylpyrrolidone. In another preferred embodiment, polyvinylpyrrolidone is first dissolved in the solvent system and adhesive mixture and rotigotine is then added to this pre- solution at room temperature . In a further' preferred embodiment, rotigotine of polymorphic Form II is used as starting material in the preparation method of the present invention.
In a further aspect, the present invention provides a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or the treatment or prevention of cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent -based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.
In one embodiment, the transdermal therapeutic system for the above use is administered once weekly and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days.
In a further embodiment, the transdermal therapeutic system for the above use is administered twice weekly and the two transdermal therapeutic systems which are administered per week have the same or a different rotigotine content and are adapted to together allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days . In one embodiment, the two transdermal therapeutic systems for the above use which are administered per week have the same rotigotine content.
In another embodiment, two transdermal therapeutic systems for the above use which are administered per week have a different rotigotine content and one of them is adapted to allow for the transdermal administration of therapeutically
effective amounts of rotigotine for at least 3 days and the other one is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 4 days.
In a further embodiment, the self-adhesive matrix layer of the transdermal therapeutic system for the above use has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer.
In a another embodiment, the self-adhesive matrix layer of the transdermal therapeutic system for the above use has a coating weight of about 100-400 g/m2 and comprises a reservoir layer containing about 9-20 wt.-% rotigotine based on the weight of the reservoir layer.
In a further embodiment, the self-adhesive matrix layer of the transdermal therapeutic system for the above use further comprises a skin adhesive layer containing rotigotine in a concentration of about 0-10 wt.-% based on the weight of the skin adhesive layer and the skin adhesive layer is provided between the reservoir layer and the release liner and has a lower rotigotine concentration than the reservoir layer.
In a preferred embodiment, the skin adhesive layer of the transdermal therapeutic system for the above use has a coating weight, which is no more than the coating weight of the reservoir layer.
In a further embodiment, the transdermal therapeutic system for the above use contains about 10-32 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer, preferably about 27 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer.
In a preferred embodiment, the reservoir layer or the reservoir layer and the skin adhesive layer, if it contains rotigotine, of the transdermal therapeutic system for the above use further contain (s) poly (N-vinyl -2 -pyrrolidone) abbreviated here as polyvinylpyrrolidone or PVP and the rotigotine to polyvinylpyrrolidone weight ratio in the respective layer is 9:2 to 9:5, preferably 9:3 to 9:5, or multiples thereof. In a further preferred embodiment, the reservoir layer and, if present, the skin adhesive layer of the transdermal therapeutic system for the above use each contain at least one, preferably two, amine-resistant silicone pressure sensitive adhesive (s) .
Brief description of figures :
Figure 1 shows a flow chart of a method for the preparation of a multi-day rotigotine containing patch of the present invention using a solvent system consisting of ethyl acetate and ethanol in a ratio of 5:1 and involving the addition of rotigotine in one portion under heating.
Figure 2a shows a flow chart of a method for the preparation of a multi-day rotigotine containing patch of the present invention using a solvent system consisting of ethyl acetate and ethanol in a ratio of 5:1 and involving the addition of rotigotine in two portions, one before and the other after PVP is added, at room temperature without heating.
Figure 2b shows a flow chart of a method for the preparation of a multi-day rotigotine containing patch of the present invention using a solvent system consisting of ethyl acetate and ethanol, involving the addition of rotigotine in one portion to a PVP solution and a silicone adhesives mixture, at room temperature without heating.
Figure 3 shows a flow chart of a method for the preparation of a multi-day rotigotine containing patch of the present invention using a solvent system consisting of heptane and ethanol in a ratio of 1:1.5.
Figure 4a shows the plasma concentration time profiles of rotigotine over 4 days after the administration of one 4 -day mono-layer TTS of Example 1 (Treatment A) in comparison to the daily administration of four 1-day patches of Comparative Example 1 (Treatment B) (n=12) .
Figure 4b shows the plasma concentration time profiles of rotigotine after the administration of one 4-day mono-layer
TTS of Example 1 (Treatment A, n=12) and one 7 -day bi- layer TTS of Example 2 (Treatment C, n=16) .
Figure 5a shows the individual rotigotine plasma concentration ratios over 4 days obtained after the single administration of the 4 -day mono- layer TTS of Example 1 in comparison to the once daily application of four 1-day patches of Comparative Example 1 in Study 1 (n=12) .
Figure 5b shows the individual rotigotine plasma concentration ratios over 7 days obtained after the single administration of the 7-day bi-layer TTS of Example 2 in comparison to the once daily application of seven 1-day patches of Comparative Example 1 in Study 2 (n=16) .
Figure 6 shows the membrane permeation profile of the 7 -day bi-layer TTS of Example 2.
Figure 7 shows the membrane permeation profile of the 7 -day bi-layer TTS of Example 2 in comparison to the 7 -day bi-layer TTS of Example 6.
Figure 8 shows the cumulative permeation profile of the 7 -day bi-layer TTS of Example 2 and the 7-day mono- layer TTS of
Example 4 in comparison to the 1-day TTS of Comparative Exam le 2.
Figure 9 shows the cumulative release (Q) of rotigotine from the 7-day bi-layer TTS of Example 2 comprising a skin adhesive layer in comparison to the 7 -day mono- layer TTS of Example 3 comprising no skin adhesive layer.
Fig 10 shows schematic drawings of possible multi-day patch variants
Detailed description
The present invention provides in a first aspect a transdermal therapeutic system, comprising
(a) a backing layer,
(b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
wherein the self-adhesive matrix layer has a coating weight of ' about 75-400 g/m2 and comprises a reservoir layer
containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer. In a further embodiment of present invention the transdermal therapeutic system, comprises
(a) a backing layer,
(b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
wherein the self-adhesive matrix layer has a coating weight of about 100-400 g/m2 and comprises a reservoir layer
containing about 9-20 wt.-% rotigotine based on the weight of the reservoir layer.
The term "transdermal therapeutic system" (TTS) as used herein refers to a matrix-type patch having a continuous
self-adhesive matrix layer in its centre portion. Such a patch consists of a backing layer, the self-adhesive matrix layer and a release liner, which is removed before use. In the present application, the terms "transdermal therapeutic system" , "TTS" and "patch" are equivalently used in order to describe the transdermal therapeutic system of the present invention .
The term "solvent -based" as used herein to describe the self- adhesive matrix layer of the transdermal therapeutic system of the present invention means that during the manufacturing process of the transdermal therapeutic system of the present invention rotigotine and the other components of the self- adhesive matrix layer are dissolved or dispersed and mixed in an organic solvent.
The term "self-adhesive matrix layer" as used herein describes the sum of adhesive containing layers, e.g. reservoir layer, skin adhesive layer and rotigotine containing skin adhesive layer and all combinations thereof as shown in Figure 10. In case the transdermal therapeutic system contains only one reservoir layer, this reservoir layer represents the self-adhesive matrix layer. The term "release liner" is used synonymous with protective foil or sheet.
This is in contrast to hot-melt manufacturing processes during which the components of a self-adhesive matrix layer of a transdermal therapeutic system are mixed in the absence of any solvent (s) in a heat molten state. Adhesives being suitable for use in a hot-melt manufacturing process exhibit a dynamic viscosity of no more than 60 Pa · s , no more than 80 Pa-s, no more than 100 Pa-s, no more than 120 Pa · s or at most 150 Pa-s at a temperature of 160 °C. Depending on the dynamic viscosity of the employed adhesive (s) at 160 °C, the addition of a softener, such as waxes, silicone oils, glycerin,
condensates from glycerin with fatty acids or polyols, or laurylacetate , or, in particular, glycerolmonolaurate , laurylacetate , waxes of the formula R-C(0)-OR', alkylmethylsiloxane waxes, siloxated polyether waxes, organic waxes or glycerin, may be required to adjust the viscosity of the adhesive (s), in particular of silicone adhesive (s), in a suitable manner during hot-melt manufacturing processes.
Silicone adhesives being suitable for preparing the solvent- based self-adhesive matrix layer of the transdermal therapeutic system of the present invention without any additive (s) exhibit a dynamic viscosity of above 150 Pa · s at a temperature of 160 °C and therefore require the addition of a softener in order to be suitable for a hot-melt manufacturing process.
In one embodiment, the solvent -based self-adhesive matrix layer of the transdermal therapeutic system of the present invention does therefore not contain an adhesive having a dynamic viscosity of no more than 60 Pa-s, no more than 80 Pa · s , no more than 100 Pa-s, no more than 120 Pa-s or at most 150 Pa-s at a temperature of 160 °C.
In another embodiment, the adhesive (s) used for preparing the solvent-based self-adhesive matrix layer of the transdermal therapeutic system of the present invention does/do not contain a softener, which after the addition to an adhesive lowers the viscosity of said adhesive to no more than 60 Pa-s, no more than 80 Pa-s, no more than 100 Pa-s, no more than 120 Pa-s or at most 150 Pa-s at a temperature of 160 °C. Said softener may be selected from the group consisting of waxes, silicone oils, glycerin, condensates from glycerin with fatty acids or polyols, and laurylacetate or which may in particular be selected from the group consisting of glycerolmonolaurate, laurylacetate, waxes of the formula R-C(0)-OR', alkylmethylsiloxane waxes, siloxated polyether waxes, organic waxes and glycerin.
The transdermal therapeutic system of the present invention comprising a solvent-based self-adhesive matrix layer and a transdermal therapeutic system obtained by a hot -melt manufacturing process are characterized by different physico- chemical properties, such as different drug release properties, even if the qualitative and quantitative composition of the respective transdermal therapeutic systems is identical.
The addition of one or more softeners to an adhesive will lower the dynamic viscosity of the adhesive in the heat molten state, but will at the same time also lower the cohesion of the self-adhesive matrix layer of an accordingly prepared final TTS thereby causing a loss of structural integrity due to an increased cold flow of the adhesive layer. This constraint is avoided by the solvent -based manufacturing process leading to the transdermal therapeutic system of the present invention.
The backing layer of the transdermal therapeutic system of the present invention is inert to the components of the self- adhesive matrix layer. It is a film being impermeable to rotigotine. Such a film may consist of polyester, polyamide, polyethylene, polypropylene, polyurethane , polyvinyl chloride or a combination of the aforementioned materials. These films may or may not be coated, e.g. with an aluminum film or with aluminum vapour or with a silicone layer. The thickness of the backing layer may be between 10 and 100 μιη, preferably between 15 and 40 μπι.
In one embodiment, the self-adhesive matrix layer is formed by a solid dispersion consisting of a dispersing agent and a dispersed phase, which is immiscible with the dispersing agent.
The dispersing agent of the solid dispersion may be any solid or semi-solid semi -permeable polymer or copolymer. The dispersing agent should provide sufficient activity and stability for the solid dispersion as well as sufficient release of rotigotine. Usually this polymer will be a pressure sensitive adhesive (PSA) or a mixture of such adhesives .
The solid dispersion forming the self-adhesive matrix layer of the transdermal therapeutic system of the present invention comprises an adhesive or a mixture of adhesives as dispersing agent and rotigotine as well as polyvinylpyrrolidone in the dispersed phase. In a preferred embodiment, the self-adhesive matrix layer of the transdermal therapeutic system of the present invention contains about 10-32 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer, preferably about 13.5 mg or about 27 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer.
Preferably, the self-adhesive matrix layer of the transdermal therapeutic system of the present invention contains about 6- 25 wt.-%, more preferred about 9-25 wt.-%, even more preferred about 9-20 wt.-% and most preferred about 9 or about 18 wt.-% rotigotine based on the weight of the self- adhesive matrix layer
In one embodiment, the self-adhesive matrix layer comprises a reservoir layer. The reservoir layer represents a matrix layer and is formed by a solid dispersion in terms of the foregoing. In a preferred embodiment, the self-adhesive matrix layer only comprises one reservoir layer and does not contain any additional matrix layer, i.e., in a preferred embodiment, the self-adhesive matrix layer represents a "mono-layer" matrix.
In another embodiment, the self-adhesive matrix layer may contain more than one reservoir layer, for example 2, 3, 4 or 5 reservoir layers. The reservoir layer contains about 9-25 wt.-%, preferably about 9-20 t.-% and most preferably about 9 wt.-% or about 18 wt.-% rotigotine based on the weight of the reservoir layer . The reservoir layer has a coating weight of about 75-400 g/m2, preferably about 100-400 g/m2, more preferably about 75-300 g/m2, more preferably about 75-200 g/m2, even more preferably 100-150 g/m2 and most preferably about 150 g/m2. In a further embodiment, the reservoir layer of the transdermal therapeutic system has a coating weight of about 75-300 g/m2, preferably about 75-200 g/m2, more preferably about 100-150 g/m2 and most preferably about 150 g/m2 and contains about 9-25 wt.-% rotigotine, preferably about 9-20 wt.-% rotigotine, more preferably about 9 wt.-% or about 18 wt.-% rotigotine based on the weight of the reservoir layer.
In a another embodiment, the reservoir layer of the transdermal therapeutic system has a coating weight of about 75-300 g/m2, preferably of about 75-200 g/m2, more preferably about 100-150 g/m2 and most preferably about 150 g/m2 and contains about 9-25 wt.-% rotigotine, preferably about 9-20 wt.-% rotigotine, more preferably about 9 wt . -% or about 18 wt.-% rotigotine based on the weight of the reservoir layer and a skin adhesive layer that has a coating weight of about 10-150 g/m2.
In a further embodiment, the self-adhesive matrix layer further comprises a skin adhesive layer. Similar to the reservoir layer, the skin adhesive layer represents a matrix layer and is preferably formed by a solid dispersion in terms
of the foregoing. The skin adhesive layer is provided between the reservoir layer and the release liner. In one embodiment, the skin adhesive layer contains no active ingredient, i.e. no rotigotine. In another embodiment, the skin adhesive layer contains rotigotine.
In a preferred embodiment, the self-adhesive matrix layer comprises a reservoir layer and a skin adhesive layer and does not contain any additional matrix layer, i.e., in a preferred embodiment, the self-adhesive matrix layer represents a "bi-layer" matrix.
The skin adhesive layer avoids a direct skin contact of the reservoir layer, which contains in some embodiments a high concentration of rotigotine, which would potentially cause local skin irritation, or might show diminished skin adhesiveness due to the high drug load. The skin adhesive layer therefore contains either no rotigotine or, if it contains rotigotine, has a lower rotigotine concentration than the reservoir layer, if the rotigotine concentration of the latter exceeds 9 wt.-%. For example, results obtained for the daily application of a TTS having a self-adhesive matrix layer only comprising a reservoir layer, i.e. a "mono-layer" matrix, containing 9 wt.-% rotigotine and 4 wt.-% PVP, have shown a good skin tolerability . The composition of the respective reservoir layer thus also represents a reasonable composition for a skin adhesive layer of a self-adhesive bi- layer matrix of the transdermal therapeutic system of the present invention. In a preferred embodiment, the self- adhesive matrix layer therefore is built up of one or more reservoir layer (s) and a skin adhesive layer, wherein the rotigotine/PVP concentration is increasing from the skin towards the backing layer in order to provide for sufficient skin tolerability, sufficient tack of the skin adhesive layer and a high drug concentration in the reservoir layer. Moreover, adequately adjusting the rotigotine/PVP content in the reservoir layer (s) and the skin adhesive layer allows for
modifying the onset of drug release and the release profile of the transdermal therapeutic system of the present invention in vivo. The skin adhesive layer contains rotigotine in a concentration of about 0-10 wt.-%, preferably about 0-9 wt.-% and most preferably about 6-9 wt.-% based on the weight of the skin adhesive layer, and has a lower rotigotine concentration than the reservoir layer.
Due to the lower rotigotine concentration in the skin adhesive layer, the transdermal therapeutic system of the present invention comprising a reservoir layer and a skin adhesive layer represents a gradient system being characterized by an increase of the rotigotine concentration from the surface of the skin adhesive layer being in contact with the patient's skin upon administration towards the reservoir layer and the backing layer. The skin adhesive layer has a coating weight of about 10-150 g/m2, preferably about 15-120 g/m2 , such as e.g. about 15-50 g/m2 or about 50-100 g/m2.
In a preferred embodiment, the coating weight of the skin adhesive layer is no more than the coating weight of the reservoir layer.
In a further preferred embodiment, the reservoir layer has a coating weight of about 75-200 g/m2, preferably 100-150 g/m2, and more preferably 150 g/m2 and contains about 18 wt.-% rotigotine based on the weight of the reservoir layer.
In another preferred embodiment, the reservoir layer has a coating weight of about 75-200 g/m2, preferably 100-150 g/m2, and more preferably 150 g/m2 and contains about 18 wt.-¾ rotigotine based on the weight of the reservoir layer and the
skin adhesive layer has a coating weight of about 10-150 g/m2.
In another preferred embodiment, the reservoir layer and the skin adhesive layer have the same coating weight . For example, the reservoir layer and the skin adhesive layer may each have a coating weight of 100 g/m2 or 150 g/m2.
In another preferred embodiment, the skin adhesive layer has a coating weight of about 15-120 g/m2 and contains about 5-10 wt.-% rotigotine based on the weight of the skin adhesive layer .
In another preferred embodiment, the skin adhesive layer has a coating weight of about 15-50 g/m2 and contains about 0-5 wt.-% rotigotine based on the weight of the skin adhesive layer .
The term "coating weight" as used herein in connection with the skin adhesive layer or reservoir layer or self-adhesive matrix layer refers to the mass per area unit of each individual layer or the sum of individual layers after removal of the solvent, except backing layer and release liner. In this connection coating weight is synonymous with area weight.
The following table 1A shows particular preferred embodiments of the self-adhesive matrix layer of the transdermal therapeutic system of the present invention.
Table 1A Composition of preferred embodiments of the self-adhesive matrix layer of the transdermal therapeutic system of the present invention
A TTS having a self-adhesive matrix layer according to embodiment 1 of the above table allows for the transdermal administration of therapeutically effective amounts of rotigotine for at least 4 days, i.e. it represents a 4 -day patch .
A TTS having a self-adhesive matrix layer according to any of embodiments 2, 3, 4, 5 or 6 of the above table allows for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days, i.e. it represents a 7-day patch.
The term "at least" as used herein in connection with the respective number of days to describe the duration of the transdermal administration of therapeutically effective amounts of rotigotine means that rotigotine is administered for the respective number of days or more. For example, "at least 7 days" means that therapeutically effective amounts of rotigotine are administered for 7 days or more.
The term "administration of therapeutically effective amounts of rotigotine" as used herein refers to the adjustment rotigotine plasma concentrations in a patient suffering from a disease to be treated with rotigotine, which lie within the therapeutic window of rotigotine for the treatment of the respective disease. For example, by administering a therapeutically effective amount of rotigotine in the treatment of Parkinson's disease, a rotigotine plasma concentration of between about 0.2 and 1.2 ng/ml during maintenance phase is adjusted and by administering a therapeutically effective amount of rotigotine in the treatment of RLS, a rotigotine plasma concentration of between about 0.1 and 0.5 ng/ml during maintenance phase is adjusted.
The commercial rotigotine-containing Neupro° patches of the applicant allow for the transdermal administration of therapeutically effective amounts of rotigotine for 1 day and contain 4.5 mg/10 cm2 rotigotine. Based on this content, a theoretical amount of rotigotine of 18.0 mg being required for a 4 -day patch and of 31.5 mg for a 7 -day patch can be calculated.
However, it was surprisingly found that a rotigotine amount of about 13.5 mg in a TTS of the present invention was sufficient to allow for the transdermal administration of therapeutically effective amounts of rotigotine for 4 days and that a rotigotine amount of about 27.0 mg in a TTS of the present invention was sufficient to allow for the transdermal
of therapeutically effective amounts
Table IB gives an overview on the combination of modifying the coating weight of the reservoir layer and the rotigotine content within the reservoir layer in wt.-% to obtain the therapeutically effective amounts of rotigotine for application periods between 1 and 7 days. Table IB: Content of rotigotine in reservoir layer depending on the coating weight to achieve the therapeutically effective amounts for the targeted application period
*x therapeutically effective amounts in TTS
*2 reduced sufficient therapeutically effective amounts in TTS, e.g. 27mg sufficient for 7 days
In case of a gradient patch comprising a rotigotine containing skin adhesive layer according to Figure 10 the required rotigotine amount in the reservoir layer can be reduced by the rotigotine amount in the skin adhesive layer to obtain required therapeutically effective amount.
That is, a sub-additive increase of the total rotigotine content in the transdermal therapeutic system of the present invention led to the targeted constant in vivo drug release
profiles over application periods of at least 3 days and up to at least 7 days. This allows for the saving of about one daily dose of rotigotine, and associated cost of goods, for a twice weekly or once weekly administered patch according to the present invention compared to the daily administration of the patches known from the prior art .
The adhesives used in the present invention should preferably be pharmaceutically acceptable in a sense that they are biocompatible, non-sensitising and non-irritating to the skin of the patient. Particularly advantageous adhesives for use in the present invention should further meet the following requirements :
1. Retained adhesive and co-adhesive properties in the presence of moisture or perspiration under normal temperature variations, and
2. Good compatibility with rotigotine, as well as with the further excipients. Although different types of pressure sensitive adhesives may be used in the present invention, it is preferred to use lipophilic adhesives having both low drug and low water absorption capacity. Preferably, the adhesives have solubility parameters which are lower than those of rotigotine. Such preferred pressure sensitive adhesives are amine-resistant silicone pressure sensitive adhesives.
The term "amine-resistant" as used herein means that the respective adhesives being characterized as amine-resistant adhesives do not react in any way with the tertiary amino- group of rotigotine.
In one embodiment the dispersing agent comprises at least one silicone pressure sensitive adhesive and preferably a mixture of at least one high tack and at least one medium tack silicone pressure sensitive adhesive.
In a preferred embodiment, the reservoir layer and, if present, the skin adhesive layer of the transdermal therapeutic system of the present invention each contain at least one, preferably two, amine-resistant silicone pressure sensitive adhesive (s) and most preferably, a mixture of at least one high tack and at least one medium tack silicone pressure sensitive adhesive.
Especially preferred pressure sensitive silicone adhesives are of the type forming a soluble polycondensed polydimethylsiloxane (PDMS) /resin network, wherein the hydroxy groups are capped with e.g. trimethylsilyl (TMS) grou s. Preferred adhesives of this kind are the BIO-PSA silicone pressure sensitive adhesives manufactured by Dow Corning, particularly the 7-4201 and 7-4301 qualities as well as the 7-4202 and 7-4302 qualities.
In another embodiment, blends or copolymers of the above silicone adhesives with other silicone adhesives or further pressure sensitive adhesives selected from the group consisting of a styrenic polymer, a polyisobutylene , or mixtures thereof as well as an acrylate-based non-aqueous polymer adhesive may be used for preparing the reservoir layer and, if present, the skin adhesive layer of the transdermal therapeutic system of the present invention. Suitable styrenic polymers are for example styrenic triblock copolymers such as styrene-ethylene- styrene (SES) , styrene- butadiene-styrene (SBS) , styrene- isoprene- styrene (SIS) , styrene-ethylene/butylene-styrene (S-EB-S) , styrene- ethylene/butylene/propylene-styrene (S-EBP-S) , styrene- isoprene/butadiene-styrene (S-IB-S) , or mixtures thereof, optionally in combination with a styrenic diblock copolymer such as styrene-ethylene (SE) , styrene-butadiene (SB) , styrene- isoprene (SI) , styrene-ethylene/butadiene-styrene (SE-BS) , styrene-ethylene/propylene (S-EP) , or mixtures thereof. A suitable acrylate-based polymer adhesive preferably contains at least two of the following monomers :
acrylic acid, acrylamide, hexylacrylate , 2- ethylhexylacrylate , hydroxyethylacrylate , octylacrylate , butylacrylate , methylacrylate , glycidylacrylate , methacrylic acid, methacryl amide , hexylmethacrylate , 2- ethylhexylmethacrylate, octylmethacrylate , methylmethacrylate , glycidylmethacrylate , vinylacetate or vinylpyrrolidone .
In a preferred embodiment, the reservoir layer and the skin adhesive layer are both based on the same adhesive (s) . For example, the reservoir layer and the skin adhesive layer may both contain one or more amine-resistant silicone pressure sensitive adhesive (s) . Likewise, if any of the above blends or copolymers is used as adhesive in the reservoir layer, the skin adhesive layer would preferably also be based on this blend or copolymer.
Tack has been defined as the property that enables an adhesive to form a bond with the surface of another material upon brief contact under light pressure (see e . g ." Pressure Sensitive Tack of Adhesives Using an Inverted Probe Machine", ASTM D2979-71 (1982) ; H. F. Hammond in D. Satas "Handbook of Pressure Sensitive Adhesive Technology" (1989) , 2nd ed. , Chapter 4, Van Nostrand Reinhold, New York, page 38) .
Medium tack of a silicone pressure sensitive adhesive indicates that the immediate bond to the surface of another material is weaker compared to a high tack silicone adhesive. Specific tack values of silicone pressure sensitive adhesives for use in the present invention can for example be determined by the Corporate Test Method (CTM) 0991 of Dow Corning . The resin/polymer ratio of the especially preferred pressure sensitive silicone adhesives for use in the present invention is 59-61/41-39 for medium tack adhesives, whereas it is
54-56/46-44 for high tack adhesives. It is known to the skilled person that both tape and rheological properties are significantly influenced by the resin/polymer ratio (K. L. Ulman and R. P. Sweet "The Correlation of Tape Properties and Rheology" (1998), Information Brochure, Dow Corning Corp., USA) .
Blends comprising a high tack and a medium tack silicone type pressure sensitive adhesive comprising polysiloxane with a resin are advantageous in that they provide for the optimum balance between good adhesion and little cold flow. Excessive cold flow based on too soft solid dispersions is disadvantageous since it may lead to a loss of the structural integrity of the self-adhesive matrix layer of a TTS at the application site and as a consequence to silicone residues sticking on the patient's skin or clothes.
Preferably, the weight ratio of a high tack to a medium tack silicone pressure sensitive adhesive in these blends is about 1:1. However, this does not exclude employing any other weight ratio.
A mixture of the aforementioned 7-4201/7-4202 (medium tack) and 7-4301/7-4302 (high tack) qualities proved to be especially useful for the preparation of the self-adhesive matrix layer of the transdermal therapeutic system of the present invention. In such a mixture, the overall resin/polymer ratio preferably is 56-58/44-42. For the preparation of the self-adhesive matrix layer of the transdermal therapeutic system of the present invention, the employed silicone adhesives are dissolved in an organic solvent. The transdermal therapeutic system of the present invention therefore represents a solvent -based transdermal therapeutic system as it was defined in the foregoing and is different from transdermal therapeutic systems obtained by a
hot melt process. During preparation of the self-adhesive matrix layer, the organic solvent is finally evaporated.
Suitable organic solvents for use in the preparation of the transdermal therapeutic system of the present invention are alkanes, carboxylic acid ester, alcohols and ketones, for example, heptane, ethyl acetate, ethanol and acetone, as well as mixtures thereof. In a preferred embodiment, a mixture of heptane and ethanol is used as organic solvent, and in a particularly preferred embodiment, a mixture of ethyl acetate and ethanol is used as organic solvent . The solid or semi-solid semi -permeable polymer representing the dispersing agent of the solid dispersion forming the self-adhesive matrix layer has to satisfy the following requirements :
1. Sufficient solubility and permeability for the free base form of rotigotine.
2. Impermeability for the protonated form of rotigotine .
In one embodiment the solubility of rotigotine (without stabilizer) in the dispersing agent is about 5 wt.-% or below and in another embodiment about 3 wt.-% or below. In still another embodiment the solubility of rotigotine (without stabilizer) in the dispersing agent is about 2 wt.-% or below and in another embodiment it is about 0.1 wt.-% or below.
The dispersed phase of the solid dispersion comprises rotigotine in non-crystalline form and a stabilizer, for example polyvinylpyrrolidone, and optionally further pharmaceutically acceptable excipients, such as permeation enhancers and antioxidants.
Polyvinylpyrrolidone is able to stabilize solid dispersions of the non-crystalline form of rotigotine by preventing rotigotine from crystallization. In one embodiment the stabilizer is selected from polyvinylpyrrolidone and in a preferred embodiment from water soluble polyvinylpyrrolidone. Copolymers of polyvinylpyrrolidone and vinyl acetate, polyethyleneglycol , polypropyleneglycol , glycerol and fatty acid esters or copolymers of ethylene and vinylacetate might also be considered for such use.
Polyvinylpyrrolidone (PVP) is a polymer made from the monomer N-vinylpyrrolidone . It increases the cohesion of silicone adhesives. The molecular weight of polyvinylpyrrolidone can be in the range from 2,000 to 2,500,000 Dalton (g/mol) (given as weight average) , in one embodiment in the range from 700 000 to 1,500,000, in another embodiment in the range from 1,000,000 to 1,500,000 Dalton. Various grades of PVP are commercially available from e.g. BASF Aktiengesellchaft of Ludwigshafen, Germany, e.g. under the name of Kollidon. For example, the following grades of Kollidons are water soluble forms of PVP: K-12 PF (molecular weight = 2,000 - 3,000); K- 17 PF (molecular weight= 7,000 - 11,000); K-25 (molecular weight = 28,000 - 34,000); K-30 (molecular weight = 44,000 - 54,000); and K-90F (molecular weight = 1,000,000 1,500,000) . In a preferred embodiment, the molecular weight of polyvinylpyrrolidone is in the range from 28,000 to 1,500,000 Dalton (g/mol). Particularly preferred are the Kollidon grades K-25, K-30 and K-90F. The rotigotine to polyvinylpyrrolidone weight ratio in the dispersed phase is 9:2 to 9:5, preferably 9:3 to 9:5, and particularly preferred 9:4, or multiples thereof. The term "multiples thereof" as used in this context means that based on a weight ratio of rotigotine to polyvinylpyrrolidone of for example 9:4, also a weight ratio of 18:8 or 27:12, etc. is encompassed .
In a preferred embodiment, the self-adhesive matrix layer of the transdermal therapeutic system of the present invention comprises a reservoir layer and the reservoir layer contains rotigotine and polyvinylpyrrolidone and the rotigotine to polyvinylpyrrolidone weight ratio in the reservoir layer is 9:2 to 9:5, preferably 9:3 to 9:5, and particularly preferred 9:4, or multiples thereof. In another preferred embodiment, the self-adhesive matrix layer of the transdermal therapeutic system of the present invention comprises a reservoir layer and a skin adhesive layer and the reservoir layer and the skin adhesive layer, if it contains rotigotine, further contain polyvinylpyrrolidone and the rotigotine to polyvinylpyrrolidone weight ratio in the respective layer is 9:2 to 9:5, preferably 9:3 to 9:5, and particularly preferred 9:4, or multiples thereof.
A decrease of the rotigotine to polyvinylpyrrolidone weight ratio from 9:2 to 9:4 has shown to provide for good physical stability of the corresponding single-day transdermal therapeutic systems (see WO 2011/076879) . An equivalent stabilizing effect could also be shown for the multi-day transdermal therapeutic system of the present invention having a higher rotigotine/PVP load per cm2.
Suitable permeation enhancers may be selected from the group of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, glycerol or its fatty acid esters, N- methylpyrrolidone , terpenes such as limonene, [alpha] -pinene , [alpha] -terpineol , carvone, carveol, limonene oxide, pinene oxide, 1 , 8 -eucalyptol and most preferably ascorbyl palmitate. In a preferred embodiment, the TTS of the present disclosure does not contain a penetration enhancer.
Suitable antioxidants are sodium metabisulfite , ascorbyl palmitate and DL-alpha tocopherol .
In one embodiment of the invention the water content of the solid dispersion is less than 1.0 wt.-% and in another embodiment it is less than 0.5 wt.-% related to the total weight of the self-adhesive matrix layer. In one embodiment, the self-adhesive matrix layer is substantially free of water, i.e. no water is used during the manufacturing process or the water is removed during the manufacturing process as complete as possible.
In a particular preferred embodiment, the self-adhesive matrix is free of particles, which can absorb salts of rotigotine on the TTS/skin interface. Examples of particles, which can absorb salts of rotigotine on the TTS/skin interface, include silica. Such particles, which can adsorb salts of rotigotine, may represent diffusion barriers for the free base form of the drug and may result in the formation of channels inducing some permeability of the self-adhesive matrix for the protonated form of rotigotine, which is disadvantageous.
Preferably, the TTS contains less than 1 wt.-% of inorganic silicates, most preferably it is completely free from inorganic silicates.
The release liner will be removed immediately prior to use, i.e. immediately before the TTS will be brought into contact with the patient's skin. The release line may consist of polyester, polyethylene or polypropylene, which may or may not be coated, e.g. with aluminum film or aluminum vapour or fluoropolymers or with a silicone layer. Typically, the thickness of such a release liner ranges between 50 and 150 μπι . So as to facilitate removal of the release liner when wishing to apply the TTS, the release liner may comprise separate
release liner having overlapping edges, similar to the kind used with the majority of conventional plasters.
In one embodiment, the transdermal therapeutic system of the present invention has a basal surface area of 5-50 cm2, preferably 5-40 cm2 such as for example 5 cm2, 10 cm2, 15 cm2, 20 cm2, 30 cm2 or 40 cm2. The term "basal surface area" as used herein refers to the surface of the self-adhesive matrix layer being in contact with the patient's skin upon administration.
Any references to rotigotine in the context of this invention and the claims of this application mean rotigotine in the form of its free base. In some cases, however, traces of rotigotine hydrochloride may be contained in a rotigotine preparation but these traces typically do not exceed 5 wt.-%, based on the amount of the free base. More preferably the content of hydrochloride impurities should be less than 2 wt.-%, even more preferably less than 1 wt.-% and most preferably the rotigotine used in the present invention contains less than 0.1 wt.-% or no hydrochloride impurities at all.
A further step, which may be taken for reducing the amount of the salt form of rotigotine, is isolating the free base form of rotigotine in solid form prior to the preparation of the solid dispersion. Alternatively, the free base of rotigotine may be produced in situ during the manufacture of the solid dispersion by neutralizing an acid addition salt of rotigotine.
It will be understood by a person skilled in the art that rotigotine exists in various stereoisomeric forms. It thus has also to be understood that besides the S-enantiomer , i.e. rotigotine, the R-enantiomer or a mixture of the different stereoisomers may be used in the present invention. Hence, the S- or R-enantiomer or the racemate or any other
enantiomeric mixture of rotigotine may be used. Most preferred, the pure S-enantiomer , i.e. rotigotine, is used.
In the dispersed phase of the solid dispersion forming the self-adhesive matrix layer of the transdermal therapeutic system of the present invention, rotigotine is present in non-crystalline form.
In one embodiment the non-crystalline form of rotigotine is amorphous rotigotine.
The rotigotine starting material used for preparing the transdermal therapeutic system of the present invention exists in two different polymorphic states, polymorphic Form I and polymorphic Form II. Polymorphic Form II of rotigotine is described in WO 2009/068520 and has at least one of the following characteristics: a X-ray powder diffraction spectrum comprising a peak at least at one of the following °2Θ angles (± 0.2) : 12.04, 13.68, 17.72 and/or 19.01, measured with Cu-Κα irradiation (1.54060 A) ; a Raman spectrum comprising at least one peak at the following wave numbers (± 3 cm"1): 226.2, 297.0, 363.9, 737.3, 847.3, 1018.7 and/or 1354.3; a differential scanning calorimetry (DSC) peak with a Tonset at 97 °C + 2°C measured with a heating rate of 10 °C/min; and/or a melting point of 97 °C ± 2°C.
In a preferred embodiment, rotigotine of polymorphic Form II is used as starting material for preparing the transdermal therapeutic system of the present invention.
While not wishing to be bound by theory it is believed that free rotigotine is molecularly dispersed in the dispersing agent of the solid dispersion forming the self-adhesive matrix layer of the transdermal therapeutic system of the present invention and that a non-crystalline form of rotigotine is reversibly associated with PVP by forming an inner phase or microreservoir .
In one embodiment the non-crystalline form of rotigotine is amorphous rotigotine. One advantage of a stable solid drug dispersion is that it can significantly reduce constraints often caused by low drug solubility in polymers suitable for transdermal delivery. The term "microreservoirs" as used herein is meant to be understood as particulate, spatially and functionally separate compartments consisting of a mixture of rotigotine and polyvinylpyrrolidone, which are dispersed (as dispersed phase) in the dispersing agent of the solid dispersion as defined above. The term "microreservoirs" as used herein is further meant to be understood as amorphous micro- spheres dispersed in a polymer matrix and which can be differentiated from the surrounding outer phase by their high drug load in accordance to their reservoir function.
In one embodiment the solid dispersion contains 103 to 109 microreservoirs per cm2 of its surface, in another embodiment 106 to 109 microreservoirs per cm2 of its surface. This further illustrates the very small or "micro" - scopic appearance of microreservoirs of present invention.
The maximum diameter of the microreservoirs is less than the thickness of the solid dispersion, preferably up to 85 % of the thickness of the solid dispersion, particularly preferred 5 to 74 % of the thickness of the solid dispersion. For an exemplary thickness of the solid dispersion of 50 urn this
corresponds to a maximum diameter of the microreservoirs in the range of preferably up to approximately 40 to 45 i .
The term "maximum diameter" as used herein is meant to be understood as the diameter of the microreservoirs in that dimension (x- , y- , or z-dimension) , which is the largest. It is clear to the skilled person that in case of spherical diameters the maximum diameter corresponds to the microreservoir ' s diameter. However, in the case of microreservoirs, which are not shaped in the form of spheres, i.e. of different geometric forms-, the x- , y- and z- dimensions may vary greatly.
In a particularly preferred embodiment of the invention, the mean diameter of the rotigotine containing microreservoirs distributed in the solid dispersion is in the range of 1 to 40 %, even more preferred 1 to 20 %, of the thickness of the solid dispersion. For an exemplary thickness of the solid dispersion of 50 im this corresponds to a mean diameter of the microreservoirs in the range of preferably 0.5 to 20 urn .
The term "mean diameter" as used herein is defined as the mean value of the x, y, z-average diameters of all microreservoirs. The target particle size can be adjusted by the solid content and the viscosity of the solid dispersion.
The maximum and mean diameters of the microreservoirs as well as the number of microreservoirs per surface area of the solid dispersion can be determined as follows: The surface of the solid dispersion is examined with a light microscope (Leica microscope type DM/RBE equipped with a camera type DS Camera Head DS-5M) . The measurement is performed by incidental polarized light analysis using a microscope at 200x magnification. A picture analysis is performed using the software Nikon LuciaG, Version 5.30, resulting in mean and maximum diameters for each sample.
In a preferred embodiment rotigotine and polyvinylpyrrolidone are contained in the transdermal therapeutic system of the present invention in a multitude of microreservoirs . Due to the presence of rotigotine and polyvinylpyrrolidone in the self-adhesive matrix layer of the transdermal therapeutic system of the present invention in the form of distinct microreservoirs, the homogenous distribution of rotigotine within the self-adhesive matrix layer remains constant during storage. That is, the transdermal therapeutic system of the present invention is characterized by very good storage stability properties.
The transdermal therapeutic system of the present invention contains rotigotine as active ingredient. Rotigotine is a dopamine D1/D2/D3 -receptor agonist and the transdermal therapeutic system of the present invention is therefore useful in the treatment of diseases susceptible to the action of dopamine receptor agonists.
In particular, the transdermal therapeutic system of the present invention can be used in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome. Furthermore, the transdermal therapeutic system of the present invention can be used in the treatment or prevention of dopaminergic neuron loss or cognitive disorders . The use of solvent-based transdermal therapeutic systems containing rotigotine as active ingredient in the treatment of the above disease and in particular in the treatment of Parkinson' s disease and in the treatment of the restless leg syndrome is known from the prior art. This treatment usually is a permanent treatment during which one single-day transdermal therapeutic system is administered every day. In particular, the permanent treatment involves the application
of one or sometimes more transdermal therapeutic system (s) at a certain place of the patient's body, the removal of the respective patch (es) after one day of wearing and the application of one or more new patch (es) at another place of the patient's body.
In contrast, the multi-day solvent-based transdermal therapeutic system of the present invention is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3-7 days, including at least 3, at least 4, at least 5, at least 6 and at least 7 days. That is, by the transdermal therapeutic system of the present invention, the frequency of administration and the number of patches to be administered in the permanent treatment of the above diseases can be reduced, thereby providing for an improved treatment in that patient's comfort and compliance are enhanced. Moreover, due to the specific construction of the multi-day solvent -based transdermal therapeutic system of the present invention its skin tolerance is comparable to the skin tolerance of the single-day solvent -based transdermal therapeutic systems known from the prior art .
The transdermal administration of therapeutically effective amounts of rotigotine for at least 3-7 days by the transdermal therapeutic system of the present invention is achieved by choosing an appropriate composition of the self- adhesive matrix layer. As it was described above, this in particular includes appropriately adjusting the coating weight, the rotigotine content and the optional provision of a skin adhesive layer.
In a preferred embodiment, the transdermal therapeutic system of the present invention is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3, at least 4 or at least 7 days .
Most preferred, the transdermal therapeutic system of the present invention is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days.
Based on the respective composition, the multi-day solvent- based transdermal therapeutic system of the present invention can be applied in the following dosage regimens:
Table 2 Possible dosage regimens of the transdermal therapeutic system of the present invention
* The drug content of the patches allows for the transdermal administration of therapeutically effective amounts of
rotigotine for 3, 3.5, 4, 5, 6 or 7 days. Based on their
respective drug content, the patches are accordingly identified as 3-day patch, 3.5 day patch, 4-day patch, 5-day patch, 6-day patch or 7-day patch.
As discussed in the foregoing, the patches of the present invention are usually applied in a chronic treatment and should therefore preferably be administered at about the same time, e.g. at almost the same hour in the morning or in the evening. This in particular applies, when administering the patches of the present invention in accordance with one of the dosage regimens shown in Table 2.
In a particular preferred embodiment, one patch of the present invention allowing for the transdermal administration of therapeutically effective amounts of rotigotine for 7 days, i.e. a 7-day patch is administered per week at a predetermined day, corresponding to a once weekly administration of a transdermal therapeutic system of the present invention.
In another preferred embodiment, one 3 -day patch and one 4- day patch, or two 3.5 -day patches, or particularly preferred two 4 -day patches are administered per week, corresponding to a twice weekly administration of a transdermal therapeutic system of the present invention. Independent of administering one 3 -day patch and one 4 -day patch, two 3.5-day patches, or two 4-day patches, the respective patches are administered every 3rd and 4th day or every 4th and 3rd day at two predetermined days per week.
The present invention therefore also provides in a second aspect a kit comprising two transdermal therapeutic systems of the present invention, wherein the two transdermal therapeutic systems may have the same or a different rotigotine content. In one embodiment, the two transdermal therapeutic systems of the kit have a different rotigotine content and one of them is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days and the other one is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least
4 days. In a preferred embodiment, the two transdermal therapeutic systems of the kit have the same rotigotine content and each of them is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 4 days.
In a third aspect, the present invention provides a method for preparing the transdermal therapeutic system described herein .
The preparation method of the present invention comprises preparing a rotigotine containing solid dispersion, i.e. the reservoir layer and optionally the skin adhesive layer (if it contains rotigotine) forming the self-adhesive matrix layer, optionally preparing a skin adhesive layer containing no rotigotine, coating, drying or cooling and laminating to get the bulk product, converting the obtained laminate into patches via cutting, and packaging. Preparing a skin adhesive layer containing no rotigotine, involves the preparation of a solution of one or more adhesive (s), coating this solution on a release liner and drying the resulting laminate. Coating, drying and laminating as well as converting the obtained laminate into separate patches via cutting and packaging are well known steps in the preparation of transdermal therapeutic systems and these steps can be carried out as described in the prior art . Reference can for example be made to the detailed description of the preparation of the example patches in the international patent application WO 99/49852.
The rotigotine containing solid dispersion of the self- adhesive layer of the transdermal therapeutic system of the present invention can be prepared in accordance with one of the methods depicted in the flow charts of Figures 1-3.
The preparation methods described therein involve two different solvent systems, one consisting of ethyl acetate and ethanol, like for example in a ratio of 5:1 and the other consisting of heptane and ethanol, like for example in a ratio of 1:1.5.
The comparison between the different preparation methods shown in Figures 1-3 reveals that the solvent system consisting of ethyl acetate and ethanol, like for example in a ratio of 5:1 allows for a significant reduction of time needed for incorporating/dissolving PVP and thus in preparing the final patches. This reduction in time is based on the surprising finding that the solubility of PVP in the aprotic polar solvent ethyl acetate is enhanced by rotigotine by one order of magnitude. Moreover, a solvent system consisting of an aprotic polar solvent and a protic polar solvent like the solvent system consisting of ethyl acetate and ethanol, for example in a ratio of 2:1 to 5:1 is required for incorporating high rotigotine concentrations of up to about 18 wt.-% in the self-adhesive matrix layer of the transdermal therapeutic system of the present invention.
In a preferred embodiment, the preparation method of the present invention therefore involves the use of a solvent system consisting of an aprotic polar solvent and a protic polar solvent in a ratio of 2:1 to 9:1. In a more preferred embodiment, the preparation of the present invention involves the use of a solvent system consisting of a aprotic polar solvent and a protic polar solvent in a ratio of 2:1 to 6:1, preferably in a ratio of 2:1 to 5:1, more preferably in a ratio of 3:1 to 5:1, particularly preferred in a ratio of 3:1 or 5:1.
In a more preferred embodiment, the preparation method of the present invention involves the use of a solvent system consisting of a carboxylic acid ester and an aliphatic alcohol. In a particular preferred embodiment, the
preparation method of the present invention involves the use of a solvent system consisting of ethyl acetate and ethanol in a ratio of 2 : 1 to 9 : 1. In a further preferred embodiment, the preparation method of the present invention involves the use of a solvent system consisting of ethyl acetate and ethanol in a ratio of 2:1 to 6:1, preferably in a ratio of 2:1 to 5:1, more preferably in a ratio of 3:1 to 5:1, particularly preferred in a ratio of 3:1 or 5:1. The addition of a small portion of ethanol to ethyl acetate enables the formation of rotigotine/PVP droplets in ethyl acetate-based silicone adhesive solutions and allows for homogenously dispersing the rotigotine/PVP conjugate in the silicone adhesive solution at room temperature.
As shown in Figure 2a and 2b, the preparation method of the present invention can therefore be carried out at room temperature without heating. When doing so, the method may involve either (i) the addition of rotigotine in two portions, one before and the other after polyvinylpyrrolidone is added to the mixture of silicone adhesives and antioxidants prepared in the solvent system (see Figure 2a) , or (ii) the addition of rotigotine in one portion together with polyvinylpyrrolidone to the mixture of silicone adhesives and antioxidants prepared in the solvent system or (iii) the addition of rotigotine in one portion to a PVP solution and a silicone adhesives mixture (see Figure 2b) .
Thus, in a further preferred embodiment, the preparation method of the present invention is carried out at room temperature and involves the addition of rotigotine in two portions, one before and the other after polyvinylpyrrolidone is added or in another preferred embodiment the addition of rotigotine in one step and the use of a polyvinylpyrrolidone solution and silicone adhesives mixture
When adding rotigotine in one portion before polyvinylpyrrolidone is added, moderate heating to about 40°C may be useful (Figure 1) . However, this does not have any influence on the reduced time needed for the subsequent incorporation/dissolution of PVP, which is carried out at room temperature.
In a another embodiment of the present invention, the preparation method for the preparation of a transdermal therapeutic system comprising
(a) a backing layer,
(b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
comprises the steps of
i) addition of polyvinylpyrrolidone to a mixture of
carboxylic acid ester and an aliphatic alcohol, preferably ethyl acetate and ethanol,
ii) addition of sodium metabilsufite solution to mixture of step i,
iii) addition of tocopherol and ascorbylpalmitate to mixture of step ii,
iv) combining of mixture of step iii with a mixture of silicone adhesives in carboxylic acid ester, preferably ethyl acetate,
v) addition of rotigotine to combination of step iv, vi) coating of the mixture of step v onto a substrate, preferably the release liner and removal of the solvents to obtain the reservoir layer thereby forming the solvent -based self-adhesive matrix layer, vii) lamination of reservoir layer from step vi with a cover layer, preferably backing layer and
viii) punching of laminate from step vii into individual transdermal therapeutic systems.
In a further embodiment, the preparation method of the present invention involves the use of a solvent system consisting of heptane and ethanol in a ratio of 1.5:1 to
1:1.5, more preferred in a ratio of 1.4:1 and particularly- preferred in a ratio of 1:1.5. A preparation method of the present invention, wherein a solvent system consisting of heptane and ethanol in a ratio of 1:1.5 is used, is shown Figure 3.
The water content in the final patches obtained by the preparation method of the present invention is in general low enough so that no evaporation of water during preparation of the patches is necessary. Typically, the water content in a freshly prepared patch is below about 2 wt.-%.
In one embodiment, the water content of the transdermal therapeutic system of the present invention therefore is below about 2 wt.-%, preferably below about 1 wt.-% and more preferred below about 0.6 wt.-%.
For preparing the transdermal therapeutic system of the present invention, either of the two crystalline forms of rotigotine, i.e. polymorphic Form I or polymorphic Form II, may be employed as a starting material .
In a preferred embodiment, rotigotine of polymorphic Form II is used as starting material for preparing the transdermal therapeutic system of the present invention.
Based on the above described dosage regimens, the present invention provides in another aspect a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders following stroke by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent-based rotigotine containing self-adhesive matrix
layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days. All aspects, embodiments and preferred embodiments as well as combinations thereof described in the foregoing for the transdermal therapeutic system of the present invention also apply to the rotigotine-containing transdermal therapeutic system for use according to the forth aspect of the present invention.
The invention and the best mode for carrying it out will be explained in more detail in the following non-limiting examples .
Examples Example 1 4 -Day mono-layer TTS comprising a reservoir layer having a coating weight of 150 g/m2 and containing 9 wt.-% rotigotine and 2 wt.-% PVP; solvent system used for the preparation method: heptane/ethanol (1.4:1 (w/w) ) 18.44 kg silicone adhesive 7-4301 (73 wt.-% in heptane) were mixed with the following components under permanent stirring until a homogeneous dispersion was obtained:
1.2.44 kg of an ethanolic solution containing 25 wt.-% polyvinylpyrrolidone (Kollidon F 90), 0.11 wt.-% aqueous sodium metabisulfite solution (10 wt.-%), 0.25 wt.-% ascorbyl palmitate and 0.62 wt.-% DL-alpha-tocopherol ;
2. 9.131 kg of an ethanolic solution containing 2.724 kg rotigotine obtained by dissolving rotigotine of polymorphic Form I;
3. 18.43 kg of silicone adhesive 7-4201 (73 wt.-% in heptane) ; and
4. 1.579 kg heptane.
For the manufacture of the self-adhesive matrix layer, the obtained dispersion was coated onto a suitable release liner (e.g. Scotchpak™ 9744) and the solvents were continuously- removed in a drying oven at temperatures up to 80 °C in order to obtain a dry drug containing matrix having a coating weight of 150 g/m2. The dried matrix layer was then laminated with a polyester-type backing foil being siliconized on the inner surface and aluminium vapor coated on the opposite surface .
Finally, individual patches having a size of 10 cm2 were punched out of the obtained laminate and were sealed into pouches under nitrogen flow.
Example 2
7-Day bi-layer TTS comprising (a) a reservoir layer having a coating weight of 150 g/m2 and containing 18 wt.-% rotigotine and 4 wt.-% PVP and (b) a skin adhesive layer containing no rotigotine and having a coating weight of 18 g/m2; solvent system used for the preparation method: heptane/ethanol (1.4:1 (w/w) )
Preparation of the reservoir layer matrix (Step 1)
9.66 kg silicone adhesive 7-4301 (73 wt.-% in heptane) were mixed with the following components under permanent stirring until a homogeneous dispersion was obtained:
1.2.90kg of an ethanolic solution containing 25 wt.-% polyvinylpyrrolidone (Kollidon F 90), 0.11 wt.-% aqueous sodium metabisulfite solution (10 wt.-%), 0.25 wt.-% ascorbyl palmitate and 0.62 wt.-% DL-alpha-tocopherol ; 2. 6.98 kg of an ethanolic solution containing 3.26 kg rotigotine obtained by dissolving rotigotine of polymorphic Form I;
3. 9.66 kg of silicone adhesive 7-4201 (73 wt.-% in heptane) ; and
4. 0.82 kg heptane. Preparation of the skin adhesive layer (Step 2)
11.51 kg silicone adhesive 7-4301 (73 wt.-% in heptane) were mixed with 7.67 kg silicone adhesive 7-4201 (73 wt.-% in heptane) and 0.82 kg heptane. The adhesive solution was then coated onto a suitable polyester release liner (e.g. Scotchpak™ 9744) up to a coating weight of 18 g/m2. The solvent was continuously removed in a drying oven at a temperature of up to 80 °C (± 3 °C) to obtain a dry adhesive film having a coating weight of 18 g/m2.
Preparation of the final TTS (Step 3)
The dispersion obtained in Step 1 was coated onto two sheets of a suitable polyester release liner (e.g. Scotchpak™ 9744) to obtain two drug-containing reservoir layers each having a coating weight of 75 g/m2. The coated release liner sheets were placed in a drying oven and dried at a temperature of up to 80 °C (± 3 °C) to obtain two dry adhesive films each having a coating weight of 75 g/m2. The first dried drug- containing reservoir layer was laminated with (1) a polyester-type backing foil being siliconized on the inner surface and aluminium vapor coated on the opposite surface and (2) the second drug-containing reservoir layer after removal of the release liner from the surface of the first reservoir layer to be laminated in order to obtain a drug- containing reservoir layer having a coating weight of 150 g/m2.
Afterwards, the skin adhesive layer was laminated with the drug-containing reservoir layer after removal of its release liner to obtain a laminate consisting of a backing foil, a rotigotine-containing reservoir layer having a coating weight
of 150 g/m2, a skin adhesive layer having a coating weight of 18 g/m2 and a release liner. The whole laminate was dried at a temperature of up to 80 °C (± 3 °C) . Finally, individual patches having a size of 10 cm2 were punched out of the complete laminate and sealed into pouches.
Comparative Example 1
Single-day mono- layer TTS comprising a reservoir layer having a coating weight of 50 g/m2 and containing 9 wt.-% rotigotine and 2 wt.-% PVP; solvent system used for the preparation method: heptane/ethanol (1.4:1 (w/w) )
The patches of Comparative Example 1 were manufactured according to the method described in Example 1, but with a coating weight of 50 g/m2 instead of 150 g/m2.
The composition of the patches of Examples 1 and 2 as well as Comparative Example 1 are depicted in Table 3.
Composition of the patches of Examples 1 and 2 and Comparative
*For the preparation of the respective example patches rotigotine of polymorphic Form I was used as starting material . The final patches contain rotigotine in non-crystalline form.
In vivo drug absorption test
In order to monitor the absorption of rotigotine by the human skin using the transdermal therapeutic systems of Examples 1
and 2 and Comparative Example 1 two pilot bioavailability (BA) studies over 4 days (Study 1) and 7 days (Study 2) , respectively, were carried out. Study 1
A single application of one TTS of Example 1 for 4 days was compared in healthy male subjects with a once-daily application of the TTS of Comparative Example 1 over 4 days in a single-site, open-label, randomized, crossover trial to evaluate the pharmacokinetics of the two different patch formulations. Subjects received one patch of Example 1 for 4 days (Treatment A) or four single patches of Comparative Example 1 at 4 consecutive days (Treatment B) in a randomized sequence (A-B or B-A) . Individual rotigotine plasma concentrations were analysed for 12 subjects by means of liquid chromatography and mass spectroscopy. The lower limit of quantification (LOQ) was 0.01 ng/ml . Study 2
A single application of one TTS of Example 2 for 7 days was compared in healthy male subjects with a once-daily application of the TTS of Comparative Example 1 over 7 days in a single-site, open-label, randomized, crossover trial to evaluate the pharmacokinetics of the two different patch formulations. Subjects received one patch of Example 2 for 7 days (Treatment C) or seven single patches of Comparative Example 1 at 7 consecutive days (Treatment D) in a randomized sequence (C-D or D-C) . Individual rotigotine plasma concentrations were analysed for 16 subjects by means of liquid chromatography and mass spectroscopy. The lower limit of quantification (LOQ) was 0.01 ng/ml. In addition the residual drug content remaining in the patches after application in Study 1 was determined by a validated HPLC method. From these data the mean apparent dose
which was released by the patch to the skin application site was estimated by the difference between declared drug content of the patch and its mean content after removal from the skin .
The in vivo drug absorption was calculated from the plasma concentration data according to the Wagner-Nelson method (Malcom Rowland, Thomas N. Tozer (Eds.) "Estimation of Adsorption Kinetics from Plasma Concentration Data" in Clinical Pharmacokinetics , pp. 480-483, Williams & Wilkins, 1995); 100 % = absorption rate measured after 4 days.
Results - Plasma concentration time profiles The plasma concentration time profiles measured for Treatments A and B in Study 1 are depicted in Figure 4a. The administration of a single 4-day patch manufactured as described under Example 1 was found to be bioequivalent to the daily administration of 4 single-day patches of Comparative Example 1.
The administration of a single 7 -day patch manufactured as described under Example 2 (Treatment C) was found in Study 2 to be almost bioequivalent to the daily administration of 7 single-day patches of Comparative Example 1 (Treatment D) , although only 27 mg of rotigotine were administered by the 7- day patch of Example 2 instead of 7x4.5 mg, i.e. 31.5 mg, rotigotine, which were administered by 7 single-day patches of Comparative Example 1. That is, one daily dose of rotigotine of 4.5 mg could be saved during Treatment C in comparison to Treatment D.
Upon normalization by the apparent dose, the values for AUC and Cmax showed a supra bioavailability, i.e. an appreciably larger bioavailability, of 120 % for the AUC and 126 % for
Cmax ·
When the rotigotine content of a 7-day patch was adapted in accordance with the rotigotine content of 7 single-day patches, subjects/patients would thus receive about 20 % more rotigotine than could be expected based on the bioavailability of rotigotine upon administration by a single-day patch.
The plasma concentration time profiles measured for the 4 -day patch of Example 1 in Study 1 and for the 7-day patch of Example 2 in Study 2 are depicted in Figure 4b.
By comparing the variations of the mean plasma concentrations within one day for the single and the once daily application over 4 and 7 days, it becomes evident that the mean plasma concentrations of the multi-day patches of Examples 1 and 2 are on average characterized by fewer fluctuations within a 24 h interval than the mean plasma concentrations obtained for the once daily administered patches of Comparative Example 1. That is, due to the removal of one patch and the consecutive application of a fresh patch onto another skin application site, the daily administration of the patches of Comparative Example 1 apparently led to larger variations.
Accordingly, individual plasma concentrations measured over 4 and 7 days after the single administration of the multi-day patches of Examples 1 and 2 and after the daily administration of four or seven single-day patches of Comparative Example 1 at the time of patch replacement of the single day patches of Comparative Example 1 were found to be consistently higher for the multi-day patches of Examples 1 and 2 in most cases. Consequently, as shown in Figures 5a and 5b, the rotigotine plasma concentration ratio of the patch of Example 1 to the patches of Comparative Example 1 and of the patch of Example 2 to the patches of Comparative Example 1 was above 1 during the 4 -day treatment as well as during the 7-day treatment for the majority of subjects.
Results - Apparent dose determination
The mean apparent drug doses released to the skin in BA Study 1 as well as the mean drug depletion rate calculated on the basis of the nominal rotigotine content in the respective patches are shown in Table 4a. The applied total dose, i.e. the nominal rotigotine content of the applied patches, as well as the mean drug quantity saved by the multi -day patch of Example 1 in comparison to the 4 single-day patches of Comparative Example 1 are shown in Table 4b.
Table 4a Result of apparent dose determinations (= estimated drug release in vivo) and corresponding mean depletion rates in BA Study 1
Table 4b Comparison of the total (nominal) rotigotine doses applied during Treatment A and Treatment B in BA Study 1 and corresponding mean drug quantity saved by the multi-day patch of Example 1 in comparison to the 4 single-day patches of Comparative Example 1
Applied total
Mean drug
dose
quantity saved
[mg/10 cm2] Coating
by Treatment A
Sample (= total weight
in comparison n
(nomina1) drug 150 [g/m2] to Treatment B
content of the
patch (es) )
4.5 mg/4 d
Example 1
13.5 150 12 (Treatment A)
1.1 mg/24 h
Comparative
Example 1 18.0 50 -/- 12 (Treatment B)
Despite a lower mean apparent dose delivered by the TTS of Example 1, bioequivalence to the daily application of 4 patches of Comparative Example 1 over 4 days could be demonstrated. This observation indicates that the daily administration of a single-day TTS requires more drug than the single administration of one multi -day TTS over the same period of time for obtaining bioequivalent rotigotine plasma concentrations. From the difference in the mean apparent dose between the two bioequivalent medications shown in Table 4a the mean additional need of rotigotine drug substance for the once daily administration with single-day patches can be estimated to be approximately 0.4 mg/10 cm2/day in the steady state .
Tolerability and skin adhesiveness
In BA Studies 1 and 2, the patches of Examples 1 and 2 as well as Comparative Example 1 were generally well tolerated. Skin tolerability and adhesiveness of all patches were good during either treatment .
Surprisingly, incidence of overall adverse effects was lower for the single administration of the multi-day patches of Examples 1 and 2 compared to the daily administration of the single-day patches of Comparative Example 1. As such, the pilot BA studies did not indicate any inferiority concerning tolerability of the multi-day transdermal therapeutic systems of the present invention in comparison to the daily administration of conventional single-day transdermal therapeutic systems.
Good adhesiveness of the multi-day patches of Example 1 having a coating weight of 150 g/m2 and Example 2 having a coating weight of 168 g/m2 in vivo was consistent with good peel adhesion properties observed in vitro.
Example 3
7-Day bi-layer TTS comprising (a) a reservoir layer having a coating weight of 150 g/m2 and containing 18 wt.-% rotigotine and 8 wt.-% PVP and (b) a skin adhesive layer containing no rotigotine and having a coating weight of 18 g/m2; solvent system used for the preparation method: ethyl acetate/ethanol (5:1 (w/w) ) Preparation of the reservoir layer matrix (Step 1)
0.061 g DL-a-Tocopherol , 0.024 g ascorbyl palmitate and 0.020 g of an aqueous sodium metabisulfite solution (10 wt.-%) were mixed with 6.0 g anhydrous ethanol to obtain a clear solution.
38.0 g silicone adhesive 7-4202 (59.1 wt.-% in ethyl acetate) and 36.9 g silicone adhesive 7-4302 (60.9 wt.-% in ethyl acetate) were added to the obtained solution of antioxidants and stirred at 400 rpm. After approximately 10 min, 11.0 g rotigotine of polymorphic Form II were added while stirring. The mixture was heated up to 40 °C and stirred at 400 rpm until a homogenous dispersion was obtained. Thereafter 4.9 g polyvinyl pyrrolidone (Kollidon 90F) were added to this mixture while stirring. The mixture was stirred at 600 rpm until a homogeneous dispersion was obtained.
Preparation of the skin adhesive layer (Step 2) 33.84 g of silicone adhesive 7-4202 (59.1 wt.-% in ethyl acetate) were mixed with 49.26 g of silicone adhesive 7-4302 (60.9 wt.-% in ethyl acetate). The adhesive solution was then coated onto a suitable polyester release liner (e.g. Scotchpak™ 9744) up to a coating weight of 18 g/m2. The coated release liner was placed in a drying oven and dried at 50 °C for about 30 min and at 115 °C for about 10 min.
Preparation of the final TTS (Step 3)
The dispersion obtained in Step 1 was coated onto two sheets of a suitable polyester release liner (e.g. Scotchpak™ 9744) to obtain two drug-containing reservoir layers each having a coating weight of 75 g/m2. The coated release liner sheets were placed in a drying oven and dried at 50 °C for about 30 min and then at 115 °C for about 10 min. The first dried drug-containing reservoir layer was laminated with (1) a polyester-type backing foil and (2) the second drug- containing reservoir layer after removal of the release liner from the surface of the first reservoir layer to be laminated in order to obtain a drug-containing reservoir layer having a coating weight of 150 g/m2.
The lamination with only (1) a polyester-type backing foil results in only one drug-containing reservoir layer having a coating weight of 75 g/m2 which leads to a transdermal therapeutic system with a shorter application time of exemplarily 3.5 days.
Afterwards, the skin adhesive layer was laminated with the drug-containing reservoir layer after removal of its release liner to obtain a laminate consisting of a backing foil, a rotigotine-containing reservoir layer having a coating weight of 150 g/m2, a skin adhesive layer having a coating weight of 18 g/m2 and a release liner. The whole laminate was dried at a temperature of 115 °C for about 10 min. Finally, individual patches having a size of 10 cm2 were punched out of the complete laminate and sealed into pouches.
Example 4
7 -Day mono- layer TTS comprising a reservoir layer having a coating weight of 150 g/m2 and containing 18 wt.-% rotigotine and 8 wt.-% PVP; solvent system used for the preparation method: ethyl acetate/ethanol (5:1 (w/w) )
The patches of Example 4 were manufactured according to the method described in Example 3, but without adding a skin adhesive layer. Example 5
7-Day mono-layer TTS comprising a reservoir layer having a coating weight of 300 g/m2 and containing 9 wt.-% rotigotine and 4 wt.-% PVP; solvent system used for the preparation method: ethyl acetate/ethanol (5:1 (w/w) )
Preparation of the reservoir layer matrix (Step 1)
0.030 g DL-a-Tocopherol , 0.012 g ascorbyl palmitate and 0,010 g of an aqueous sodium metabisulfite solution (10 wt.-%) were mixed with 7.1 g anhydrous ethanol to obtain a clear solution .
44.7 g silicone adhesive 7-4202 (59.1 wt.-% in ethyl acetate) and 43.4 g silicone adhesive 7-4302 (60.9 wt.-% in ethyl acetate) were added to the above solution of antioxidants and stirred at 400 rpm. After approximately 10 min, 5.5 g rotigotine of polymorphic Form II were added while stirring. The mixture was heated up to 40 °C and stirred at 400 rpm until a homogenous dispersion was obtained. Thereafter, 2.4 g polyvinyl pyrrolidone (Kollidon 90F) were added to this mixture while stirring. The mixture was stirred at 600 rpm until a homogeneous dispersion was obtained. Preparation of the final TTS (Step 2)
The dispersion obtained in Step 1 was coated onto 4 sheets of a suitable polyester release liner (e.g. Scotchpak™ 9744) to obtain 4 drug-containing reservoir layers each having a coating weight of 75 g/m2. The coated release liner sheets were placed in a drying oven and dried at 50 °C for about 30 min and then at 115 °C for about 10 min. The first dried
drug-containing reservoir layer was laminated with a polyester-type backing foil on one side and, consecutively, with the 3 remaining drug-containing reservoir layers on the other side after removing the release liner foils from the surface to be laminated of the respective reservoir layers in order to obtain a laminate consisting of a backing foil, a drug-containing reservoir layer having a coating weight of 300 g/m2 and a release liner. The whole laminate was dried at a temperature of 115 °C for about 10 min. Finally, individual patches having a size of 10 cm2 were punched out of the complete laminate and sealed into pouches.
Example 6 7 -Day mono- layer TTS comprising a reservoir layer having a coating weight of 300 g/m2 and containing 9 wt.-% rotigotine and 4 wt.-% PVP; solvent system used for the preparation method: heptane/ethanol (1:1.5 (w/w) ) Preparation of the reservoir layer matrix (Step 1)
To 19.0 g of an ethanolic PVP solution (containing 12.8 wt.-% polyvinylpyrrolidone (Kollidon 90F) , 0.06 wt.-% aqueous sodium metabisulfite solution (10 wt.-%), 0.06 wt.-% ascorbyl palmitate and 0.16 wt.-% DL-alpha-tocopherol) , 5.5 g of rotigotine of polymorphic Form II were added. The mixture was stirred for 1.5 h at 60 °C. Then, 36.0 g of silicone adhesive 7-4201 (73.6 wt.-% in heptane) and 36.1 g of silicone adhesive 7-4301 (73.3 wt.-% in heptane) were added and the mixture was stirred without heating until a homogenous dispersion was obtained.
Preparation of the final TTS (Step 2) The final patches of Example 6 were manufactured according to the method described in Step 2 of Example 5.
Example 7
7-Day bi-layer TTS comprising (a) a reservoir layer having a coating weight of 100 g/m2 and containing 18 wt.-% rotigotine and 8 wt.-% PVP and (b) a skin adhesive layer having a coating weight of 100 g/m2 and containing 9 wt.-% rotigotine and 4 wt.-% PVP ("gradient system"); solvent system used for the preparation method: ethyl acetate/ethanol (5:1 (w/w) ) Preparation of the reservoir layer matrix (Step 1)
The reservoir layer was manufactured according to the method described in Step 1 of Example 3. Preparation of the skin adhesive layer (Step 2)
The skin adhesive layer was manufactured according to the method described for the reservoir layer matrix in Step 1 of Example 5.
Preparation of the final TTS (Step 3)
The final patches of Example 7 were manufactured according to the method described in Step 3 of Example 3, but with only one coating step for each of the reservoir layer and the drug-containing skin adhesive layer resulting in a coating weight of 100 g/m2 for each of the two layers.
Example 8
7-Day mono-layer TTS comprising a reservoir layer having a coating weight of 150 g/m2 and containing 18 wt.-% rotigotine and 8 wt.-% PVP; solvent system used for the preparation method: ethyl acetate/ethanol (5:1 (w/w)); solubilizing rotigotine and PVP without heating; adding rotigotine in 2 portions before and after the addition of PVP
Preparation of the reservoir layer matrix (Step 1)
0.061 g DL-a-Tocopherol , 0.024 g ascorbyl palmitate and 0.020 g of an aqueous sodium metabisulfite solution (10 wt.-%) were mixed with 6.0 g anhydrous ethanol to obtain a clear solution.
38.0 g silicone adhesive 7-4202 (59.1 wt.-% in ethyl acetate) and 36.9 g silicone adhesive 7-4302 (60.9 wt.-¾ in ethyl acetate) were added to the obtained solution of antioxidants and stirred at 400 rpm. After approximately 10 min, 5.0 g rotigotine of polymorphic Form II were added while stirring at 400 rpm until a homogenous dispersion was obtained (approx. 15 min) . Thereafter, 4.9 g polyvinylpyrrolidone (Kollidon 90F) were added to this mixture while stirring at 600 rpm until a homogeneous dispersion was obtained (approx. 45 min) . Then, 6.0 g rotigotine of polymorphic Form II were added to the mixture while stirring at 600 rpm until a homogeneous dispersion was obtained (approx. 60 min) . Preparation of the final TTS (Step 2)
The final patches of Example 8 were manufactured according to the method described in Step 3 of Example 3, but without adding a skin adhesive layer.
Example 9
7 -Day mono-layer TTS comprising a reservoir layer having a coating weight of 150 g/m2 and containing 18 wt.-% rotigotine and 8 wt.-% PVP; solvent system used for the preparation method: ethyl acetate/ethanol (3:1 (w/w) ) .
Preparation of the reservoir layer matrix (Step 1) To 19.6 g of an ethanolic PVP solution (containing 23.5 wt.-% polyvinylpyrrolidone (Kollidon 90F) , 0.12 wt.-% aqueous sodium metabisulfite solution (10 wt.-%), 0.12 wt.-% ascorbyl
palmitate and 0.29 wt.-% DL-alpha-tocopherol and 21.4 wt-% ethyl acetate), 35.6 g of silicone adhesive 7-4202 (59.1 wt . - % in ethyl acetate) and 34.6 g of silicone adhesive 7-4302 (60.9 wt.-% in ethyl acetate) were added and shortly stirred. Then, 10.3 g rotigotine of polymorphic Form II were added to the mixture while stirring. The final mixture was stirred until a homogenous dispersion was obtained.
Preparation of the final TTS (Step 2)
The final patches of Example 9 were manufactured according to the method described in Step 3 of Example 3, but without adding a skin adhesive layer.
Instead of coating reservoir layers each having a coating weight of 75 g/m2 and laminating two coated layers together to achieve the final coating weight of 150 g/m2, the coating of only one reservoir layer having a coating weight of 150 g/m2 is also possible. Comparative Example 2
Single-day mono-layer TTS comprising a reservoir layer having a coating weight of 50 g/m2 and containing 9 wt.-% rotigotine and 4 wt.-% PVP; solvent system used for the preparation method: heptane/ethanol (1.4:1 (w/w) )
Comparative Example 2 corresponds to Comparative Example 1, except for the use of rotigotine of polymorphic Form II instead of rotigotine of polymorphic Form I as starting material and an increased PVP content resulting in a rotigotine to PVP wt.-% ratio of 9:4.
Comparative Example 3 7-Day mono-layer TTS comprising a reservoir layer having a coating weight of 150 g/m2 and containing 18 wt.-% rotigotine
and 8 wt.-% PVP; solvent system used for the preparation method: heptane/ethanol (1:1.5 (w/w) )
Preparation of the reservoir layer matrix (Step 1)
11.0 g of rotigotine of polymorphic Form II and 7.9 g ethanol were added to 21.5 g of an ethanolic PVP solution (containing 22.7 wt.-% polyvinylpyrrolidone (Kollidon 90F) , 0.1 wt.-% aqueous sodium metabisulfite solution (10 wt.-%), 0.1 wt.-¾ ascorbylpalmitate and 0.3 wt.-% DL-alpha-tocopherol ) . The mixture was stirred for 1.5 h at 60 °C. Then, 30.5 g of silicone adhesive 7-4201 (73.6 wt.-% in heptane) and 30.7 g of silicone adhesive 7-4301 (73.3 wt.-% in heptane) were added and the mixture was stirred without heating until a homogenous dispersion was obtained.
Preparation of the final TTS (Step 2)
The final patches of Comparative Example 2 were manufactured according to the method described in Step 3 of Example 3, but without adding a skin adhesive layer.
The respective compositions of Examples 3-9 and Comparative Examples 2 and 3 are summarized in Table 5.
Table 5 Composition of the patches of Examples 3-9 and Comparative Examples 2 and 3
*For the preparation of the respective example patches rotigotine of polymorphic Form II was used as starting material. The final patches contain rotigotine in non-crystalline form.
X=l for silicone adhesive in heptane
X=2 for silicone adhesive in ethyl acetate
In Table 6, the composition and selected physical properties of the dispersions forming the drug containing self-adhesive matrix layer of representative example patches are shown. The dispersions were prepared in accordance with the methods described in Example 3 as well as Comparative Example 3 and were investigated in the liquid state before laminating them and before the solvents were evaporated in a drying step. The self-adhesive matrix layer of the transdermal therapeutic system described herein represents a dispersion of rotigotine/PVP droplets in a matrix of silicone adhesives and can therefore be considered as a non-aqueous emulsion. From the data shown in Table 6, it becomes apparent that the use of an ethyl acetate/ethanol solvent mixture, in contrast to a heptane/ethanol solvent mixture, leads to physically stable emulsions also at high concentrations of rotigotine in the inner and the outer phase of the emulsion (cf. Example 3 in comparison to Comparative Example 3) .
Table 6 Solvents and selected physical properties of the dispersions (i.e. non-aqueous emulsions) forming the self-adhesive matrix layer of the TTS of Example 3 as well as Comparative Example 3
API = Rotigotine
1The dispersions forming the self-adhesive matrix layer of the transdermal therapeutic systems of Example 3 as well as Comparative Example 3 were prepared in accordance with the methods described in the respective examples and were investigated in the liquid state before laminating them and before the solvents were evaporated in a drying step.
2Inner and outer phase were separated by centrifugation; drug content was determined in each phase by HPLC
3Crystallization of rotigotine was observed at room temperature after a
storage/holding time of 2 days at room temperature
Surprisingly, it was found that the solubility of PVP in ethyl acetate is enhanced by rotigotine by one order of magnitude. That is, rotigotine apparently functions as a co- solvent for PVP in an aprotic polar solvent such as ethyl acetate. This indicates that rotigotine forms an adduct with the PVP polymer and reveals a different solubility in dipolar organic solvents on the one hand and in a heptane/ethanol mixture on the other hand. Furthermore, the addition of a small portion of ethanol to ethyl acetate enables the formation of rotigotine/PVP droplets in ethyl acetate-based silicone adhesive solutions and allows for homogenously dispersing the rotigotine/PVP conjugate in the silicone adhesive solution at room temperature.
In vitro drug permeation testing across an ethylene vinyl acetate (EVA) membrane
In vitro Drug release was evaluated by a membrane permeation test performed over an extended period of time using a 51 μτη thick membrane consisting of an ethylene vinyl acetate (EVA) copolymer with 9 % vinyl acetate (CoTran™ Membrane, 3M) and the Paddle over Disk apparatus described in the United States Phamacopeia (USP) . Phosphate buffer pH 4.5 was used as acceptor medium (900 ml; 32 °C; 50 rpm) . The drug permeation rates into the acceptor medium were determined in regular intervals using a validated UV photometric or HPLC method.
In vitro drug release testing
The drug release test was performed under equivalent conditions as described for the drug permeation test, but without placing an EVA membrane between the release surface of the respective TTS and the acceptor medium. The cumulative amount of drug released into the acceptor medium was determined in regular intervals using a validated HPLC method .
Results - In vitro drug permeation across an EVA membrane
The results of the EVA membrane tests performed with sample patches of Example 3 are depicted in Figure 6.
The data show a constant drug permeation profile for the TTS of Example 3 over 7 days without any significant decline over the entire test period.
The results of the EVA membrane tests performed with sample patches of Examples 3 and 7 are depicted in Figure 7.
The data show constant and comparable drug permeation profiles for the TTS of Example 3 and the TTS of Example 7 over 7 days without any significant decline over the entire test period.
In comparison to the TTS of Example 3 comprising a skin adhesive layer containing no rotigotine, the initial flux rate was higher for the TTS, i.e. the gradient system, of Example 7. That is, a gradient system according to Example 7 offers the possibility of slightly increased drug absorption immediately after application.
In Figure 8, the cumulative permeation profiles of the 7 -day bi-layer TTS of Example 3, the 7-day mono-layer TTS of Example 5, and the 1-day TTS of Comparative Example 2 are depicted .
The data demonstrate that a prolongation of the functional life time of a TTS can be obtained by (a) increasing the thickness/coating weight of the self-adhesive matrix layer from 50 to 300 g/m2 (Example 5) without changing the 9:4 wt . - % ratio of rotigotine to PVP known from Comparative Example 2 or (b) with a bi-layer self-adhesive matrix comprising a reservoir layer having a coating weight of 150 g/m2
containing rotigotine and PVP in a wt.-% ratio of 18:8 and a skin adhesive layer having a coating weight of 18 g/m2 containing no rotigotine. Results - In vitro drug release into an acceptor medium
In Figure 9, the cumulative release (Q) of rotigotine from the 7-day bi-layer TTS of Example 3 and the 7-day mono-layer TTS of Example 4 is depicted. The patches of Examples 3 and 4 both comprise a reservoir layer having an identical composition and only differ in that the patch of Example 3 further comprises a skin adhesive layer containing no rotigotine . The data show that the drug release from the patches of Examples 3 and 4 in both cases follows a typical square root of time kinetics up to a drug depletion rate of more than 80% related to the total drug content of the reservoir layer. The slope of the regression lines is very similar and the onset of the release is only slightly delayed by the skin adhesive layer of the patch of Example 3 having a coating weight of 18 g/m2. That is, adhesion properties as well as the initial burst of the drug release can be adapted by a skin adhesive layer in accordance with drug safety needs and without compromising the release performance of a corresponding TTS.
Claims
1. Transdermal therapeutic system, comprising
(a) a backing layer,
(b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer
containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer.
2. Transdermal therapeutic system according to claim 1, comprising
(a) a backing layer,
(b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
wherein the self-adhesive matrix layer has a coating weight of about 100-400 g/m2 and comprises a reservoir layer
containing about 9-20 wt.-% rotigotine based on the weight of the reservoir layer.
3. The transdermal therapeutic system according to any one of claims 1-2, wherein the self-adhesive matrix layer further comprises a skin adhesive layer containing rotigotine in a concentration of about 0-10 wt.-% based on the weight of the skin adhesive layer and wherein the skin adhesive layer is provided between the reservoir layer and the release liner and has a lower rotigotine concentration than the reservoir layer .
4. The transdermal therapeutic system according to any one of claims 1-3, wherein the reservoir layer has a coating weight of about 75-300 g/m2, preferably about 75-200 g/m2, more preferably about 100-150 g/m2 and contains about 18 wt . - % rotigotine based on the weight of the reservoir layer.
5. The transdermal therapeutic system according to claim
4, wherein the reservoir layer has a coating weight of about 75-300 g/m2, preferably about 75-200 g/m2, more preferably about 100-150 g/m2 g/m2 and contains about 18 wt.-% rotigotine based on the weight of the reservoir layer and the skin adhesive layer has a coating weight of about 10-150 g/m2.
6. The transdermal therapeutic system according to claim
5, wherein the skin adhesive layer has a coating weight of about 15-120 g/m2 and contains about 5-10 wt.-% rotigotine based on the weight of the skin adhesive layer.
7. The transdermal therapeutic system according to claim 5, wherein the skin adhesive layer has a coating weight of about 15-50 g/m2 and contains about 0-5 wt.-% rotigotine based on the weight of the skin adhesive layer.
8. The transdermal therapeutic system according to any one of claims 1-7, wherein the transdermal system contains about 10-32 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer, preferably about 27 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer.
9. The transdermal therapeutic system according to any one of claims 1-8, wherein the reservoir layer or the reservoir layer and the skin adhesive layer, if it contains rotigotine, further contain (s) polyvinylpyrrolidone and the rotigotine to polyvinylpyrrolidone weight ratio in the respective layer is 9:2 to 9:5, preferably 9:3 to 9:5, or multiples thereof.
10. The transdermal therapeutic system according to any one of claims 1-9, wherein the reservoir layer and, if present, the skin adhesive layer each contain at least one, preferably two, amine-resistant silicone pressure sensitive adhesive (s) .
11. The transdermal therapeutic system according to any one of claims 1-10, wherein the transdermal therapeutic system is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3-7 days .
12. The transdermal therapeutic system according to claim 11, wherein the transdermal therapeutic system is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days.
13. Kit comprising two transdermal therapeutic systems according to any one of claims 1-12, wherein the two transdermal therapeutic systems have the same or a different rotigotine content.
14. Kit according to claim 13, wherein the two transdermal therapeutic systems have the same rotigotine content and each of them is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 4 days .
15. Method for the preparation of the transdermal therapeutic system according to any one of claims 1-12.
16. The preparation method according to claim 15, wherein a solvent system consisting of an aprotic polar solvent and a protic polar solvent in a ratio of 2:1 to 9:1 is used.
17. The preparation method according to claim 15 or 16, wherein a solvent system consisting of an aprotic polar solvent and a protic polar solvent in a ratio of 2:1 to 6:1, preferably in a ratio of 2:1 to 5:1, more preferably in a ratio of 3:1 to 5:1, particularly preferred in a ratio of 3:1 or 5:1 is used.
18. The preparation method according to any of claims 15 to
17, wherein the solvent system consisting of a carboxylic acid ester and an aliphatic alcohol is used.
19. The preparation method according to any of claims 15 to
18, wherein the solvent system consisting of ethyl acetate and ethanol is used.
20. The preparation method according to any of claims 15 to 19, wherein the solvent system consisting of ethyl acetate and ethanol in a ratio of 2:1 to 6:1, preferably in a ratio of 2:1 to 5:1, more preferably in a ratio of 3:1 to 5:1, particularly preferred in a ratio of 3:1 or 5:1 is used
21. The preparation method according to any of claims 15- 20, wherein the method is carried out at room temperature and rotigotine is added in two portions, one before and the other after polyvinylpyrrolidone is added.
22. The preparation method according to any of claims 15-21 wherein the method is carried out at room temperature and rotigotine is added in one portion to a polyvinylpyrrolidone solution and a silicone adhesives mixture.
23. The method according to any one of claims 15-22, wherein rotigotine of polymorphic Form II is used as starting material .
24. The preparation method according to claim 15, wherein a solvent system consisting of heptane and ethanol in a ratio of 1.5:1 to 1:1.5 is used.
25. Transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, anxiety, AHDS , fibromyalgia, the restless-legs syndrome and for use in the treatment or
prevention of dopaminergic neuron loss or the treatment or prevention of cognitive disorders, dementia or lewy body disease by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent-based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.
26. The transdermal therapeutic system for use according to claim 25, wherein the transdermal therapeutic system is administered once weekly and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days.
27. The transdermal therapeutic system for use according to claim 25, wherein the transdermal therapeutic system is administered twice weekly and wherein the two transdermal therapeutic systems which are administered per week have the same or a different rotigotine content and are adapted to together allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 7 days .
28. The transdermal therapeutic system for use according to claim 27, wherein the two transdermal therapeutic systems which are administered per week have the same rotigotine content .
29. The transdermal therapeutic system for use according to claim 27, wherein the two transdermal therapeutic systems which are administered per week have a different rotigotine content and one of them is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days and the other one is adapted to allow for the transdermal administration of
therapeutically effective amounts of rotigotine for at least 4 days .
30. The transdermal therapeutic system for use according to any one of claims 25-29, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer.
31. The transdermal therapeutic system for use according to any one of claims 25-30, wherein the self-adhesive matrix layer has a coating weight of about 100-400 g/m2 and comprises a reservoir layer containing about 9-20 wt.-% rotigotine based on the weight of the reservoir layer.
32. The transdermal therapeutic system for use according to any one of claims 30-31, wherein the self-adhesive matrix layer further comprises a skin adhesive layer containing rotigotine in a concentration of about 0-10 wt.-% based on the weight of the skin adhesive layer and wherein the skin adhesive layer is provided between the reservoir layer and the release liner and has a lower rotigotine concentration than the reservoir layer.
33. The transdermal therapeutic system for use according to any one of claims 30-32, wherein the skin adhesive layer has a coating weight, which is no more than the coating weight of the reservoir layer.
34. The transdermal therapeutic system for use according to any one of claims 25-33, wherein the transdermal therapeutic system contains about 10-32 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer, preferably about 27 mg rotigotine/10 cm2 surface of the self-adhesive matrix layer.
35. The transdermal therapeutic system for use according to any one of claims 30-34, wherein the reservoir layer or the
reservoir layer and the skin adhesive layer, if it contains rotigotine, further contain (s) polyvinylpyrrolidone and the rotigotine to polyvinylpyrrolidone weight ratio in the respective layer is 9:2 to 9:5, preferably 9:3 to 9:5, or multiples thereof.
36. The transdermal therapeutic system for use according to any one of claims 30-35, wherein the reservoir layer and, if present, the skin adhesive layer each contain at least one, preferably two, amine-resistant silicone pressure sensitive adhesive ( s ) .
37. A method for the preparation of a transdermal therapeutic system according to any of claims 1-12 comprising (a) a backing layer,
(b) a solvent -based self-adhesive matrix layer containing rotigotine as active ingredient, and
(c) a release liner,
comprising the steps of
ix) addition of polyvinylpyrrolidone to a mixture of
carboxylic acid ester and an aliphatic alcohol, preferably ethyl acetate and ethanol ,
x) addition of sodium metabilsufite solution to mixture of step i,
xi) addition of tocopherol and ascorbylpalmitate to mixture of step ii,
xii) combining of mixture of step iii with a mixture of silicone adhesives in carboxylic acid ester, preferably ethyl acetate,
xiii) addition of rotigotine to combination of step iv, coating of the mixture of step v onto a substrate, preferably the release liner and removal of the solvents to obtain the reservoir layer thereby forming the solvent-based self-adhesive matrix layer, xv) lamination of reservoir layer from step vi with a cover layer, preferably backing layer and
xvi) punching of laminate from step vii into individual transdermal therapeutic systems.
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2015006357A MX354502B (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine. |
| BR112015011729-5A BR112015011729B1 (en) | 2012-11-22 | 2013-11-21 | TRANSDERMAL THERAPEUTIC SYSTEM, KIT COMPRISING IT AND METHOD FOR PREPARING IT |
| EA201500553A EA201500553A1 (en) | 2012-11-22 | 2013-11-21 | MULTI-DAY PLASTER FOR INTERCUTABLE ROTIGOTIN INTRODUCTION |
| IN2488DEN2015 IN2015DN02488A (en) | 2012-11-22 | 2013-11-21 | |
| CN201380054953.XA CN104736146B9 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for transdermal administration of rotigotine |
| EP13795432.7A EP2922533B1 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
| CN201910246426.8A CN110200950B (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for transdermal administration of rotigotine |
| ES13795432.7T ES2639294T3 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for transdermal administration of rotigotine |
| JP2015543338A JP6301356B2 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for transdermal administration of rotigotine |
| CA2887085A CA2887085C (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
| US14/443,210 US11389410B2 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
| KR1020157008077A KR20150094588A (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
| AU2013350037A AU2013350037B2 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
| US17/589,262 US20220151949A1 (en) | 2012-11-22 | 2022-01-31 | Multi-Day Patch for the Transdermal Administration of Rotigotine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12193808 | 2012-11-22 | ||
| EP12193808.8 | 2012-11-22 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/443,210 A-371-Of-International US11389410B2 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
| US17/589,262 Division US20220151949A1 (en) | 2012-11-22 | 2022-01-31 | Multi-Day Patch for the Transdermal Administration of Rotigotine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014079573A1 true WO2014079573A1 (en) | 2014-05-30 |
Family
ID=47215446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2013/003515 WO2014079573A1 (en) | 2012-11-22 | 2013-11-21 | Multi-day patch for the transdermal administration of rotigotine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11389410B2 (en) |
| EP (1) | EP2922533B1 (en) |
| JP (1) | JP6301356B2 (en) |
| KR (1) | KR20150094588A (en) |
| CN (2) | CN104736146B9 (en) |
| AR (1) | AR093481A1 (en) |
| AU (1) | AU2013350037B2 (en) |
| BR (1) | BR112015011729B1 (en) |
| CA (1) | CA2887085C (en) |
| EA (1) | EA201500553A1 (en) |
| ES (1) | ES2639294T3 (en) |
| IN (1) | IN2015DN02488A (en) |
| MX (1) | MX354502B (en) |
| TW (1) | TW201431570A (en) |
| WO (1) | WO2014079573A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015177204A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
| WO2015177212A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| WO2016096840A1 (en) * | 2014-12-16 | 2016-06-23 | Amarin Technologies S.A. | A device for the transdermal delivery of rotigotine |
| EP2922533B1 (en) | 2012-11-22 | 2017-06-14 | UCB Biopharma SPRL | Multi-day patch for the transdermal administration of rotigotine |
| WO2019043172A1 (en) * | 2017-09-04 | 2019-03-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an emulsifier |
| WO2019077118A1 (en) * | 2017-10-20 | 2019-04-25 | Amw Gmbh | Stabilized transdermal delivery system |
| US11033723B2 (en) | 2013-07-03 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising an electronic component |
| EP3854388A1 (en) * | 2020-01-24 | 2021-07-28 | Luye Pharma Switzerland AG | Transdermal therapeutic system comprising rotigotine and at least one non-amine-resistant silicone adhesive |
| US11426359B2 (en) | 2014-05-20 | 2022-08-30 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| US11648213B2 (en) | 2018-06-20 | 2023-05-16 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| RU2798017C2 (en) * | 2018-06-20 | 2023-06-14 | Лтс Ломанн Терапи-Систем Аг | Transdermal therapeutic system containing asenapine |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018199018A1 (en) * | 2017-04-26 | 2018-11-01 | ニプロ株式会社 | Transdermally absorbable preparation and method for producing same |
| JPWO2018199015A1 (en) * | 2017-04-26 | 2020-03-12 | ニプロ株式会社 | Transdermal preparation and method for producing the same |
| EP3861999A4 (en) * | 2018-10-01 | 2022-06-22 | Hisamitsu Pharmaceutical Co., Inc. | Asenapine-containing adhesive patch |
| KR20200046461A (en) * | 2018-10-24 | 2020-05-07 | 에스케이케미칼 주식회사 | Composition comprising non-crystalline rotigotine and manufacturing method thereof |
| US20220117934A1 (en) * | 2019-02-15 | 2022-04-21 | Hisamitsu Pharmaceutical Co., Inc. | Rotigotine stabilization method |
| JP6872675B1 (en) * | 2019-06-14 | 2021-05-19 | 久光製薬株式会社 | Rotigotine-containing patch |
| KR102260202B1 (en) * | 2019-10-30 | 2021-06-03 | 에바바이오 주식회사 | Ionic Mixture for Rotigotine and Uses thereof |
| CA3162229A1 (en) * | 2019-12-20 | 2020-12-30 | Patrick Mohr | Transdermal therapeutic system containing agomelatine |
| CN113384560A (en) * | 2021-07-07 | 2021-09-14 | 华健医疗(深圳)有限公司 | Compound transdermal patch of rotigotine and nicotine for treating or preventing nervous system diseases and preparation method thereof |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999049852A1 (en) | 1998-03-30 | 1999-10-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
| WO2002015903A2 (en) | 2000-08-24 | 2002-02-28 | Schwarz Pharma Ag | Novel pharmaceutical composition for administering n-0923 |
| WO2002089777A1 (en) | 2001-05-08 | 2002-11-14 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of parkinson's disese |
| WO2003092677A1 (en) | 2002-05-06 | 2003-11-13 | Schwarz Pharma Ag | Trans-epicutaneous administration form for treating restless leg syndrome |
| WO2004012721A2 (en) | 2002-07-30 | 2004-02-12 | Schwarz Pharma Ag | Hot melt tts for administering rotigotine |
| WO2004050083A1 (en) | 2002-12-02 | 2004-06-17 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of parkinson's disease |
| US20040137045A1 (en) * | 2002-07-30 | 2004-07-15 | Armin Breitenbach | Hot-melt TTS for administering Rotigotine |
| WO2005009424A1 (en) | 2003-07-26 | 2005-02-03 | Schwarz Pharma Ag | Use of rotigotine for the treatment of depression |
| WO2005063236A1 (en) | 2003-12-23 | 2005-07-14 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| WO2005063237A1 (en) | 2003-12-24 | 2005-07-14 | Schwarz Pharma Ag | Use of rotigotine for the treatment or prevention of dopaminergic neurone loss |
| WO2005092331A1 (en) | 2004-03-24 | 2005-10-06 | Schwarz Pharma Ag | Use of rotigotine for treating and preventing parkinson's plus syndrome |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| WO2009068520A2 (en) | 2007-11-28 | 2009-06-04 | Schwarz Pharma Ag | Polymorphic form of rotigotine |
| WO2011076879A1 (en) | 2009-12-22 | 2011-06-30 | Ucb Pharma Gmbh | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3315272C2 (en) | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmaceutical product and process for its manufacture |
| US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| US5032207A (en) | 1988-03-04 | 1991-07-16 | Noven Pharmaceuticals, Inc. | One-step method for forming a pressure-sensitive adhesive transdermal drug device |
| US5405486A (en) | 1988-03-04 | 1995-04-11 | Noven Pharmaceuticals, Inc. | Apparatus for forming a transdermal drug device |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US4814168A (en) | 1988-03-04 | 1989-03-21 | Noven Pharmaceuticals, Inc. | Transdermal multipolymer drug delivery system |
| US4994267A (en) | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4994278A (en) | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Breathable backing |
| US5300291A (en) | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
| ES2097145T3 (en) | 1990-03-28 | 1997-04-01 | Noven Pharma | METHOD AND DEVICE FOR THE RELEASE OF DRUGS IN THE SKIN. |
| WO1992019451A1 (en) | 1991-04-25 | 1992-11-12 | Noven Pharmaceuticals, Inc. | Method and apparatus for forming a transdermal drug device |
| US5387189A (en) | 1993-12-02 | 1995-02-07 | Alza Corporation | Electrotransport delivery device and method of making same |
| KR100611245B1 (en) | 1998-03-20 | 2006-08-10 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | Receiver with a clock signal generator and method of tuning the receiver |
| US6757560B1 (en) | 1999-04-09 | 2004-06-29 | Novosis Pharma Ag | Transdermal delivery system (TDS) with electrode network |
| US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US6317630B1 (en) | 1999-01-29 | 2001-11-13 | Yossi Gross | Drug delivery device |
| CA2376368C (en) | 1999-06-08 | 2009-08-11 | Altea Technologies, Inc. | Apparatus for microporation of biological membranes using thin film tissue interface devices, and method therefor |
| IL147247A0 (en) | 1999-07-02 | 2002-08-14 | Lohmann Therapie Syst Lts | Microreservoir system based on polysiloxanes and ambiphilic solvents |
| DE10012908B4 (en) * | 2000-03-16 | 2005-03-17 | Lts Lohmann Therapie-Systeme Ag | Stabilized supersaturated transdermal therapeutic matrix systems and methods for their preparation |
| US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
| US20040138299A1 (en) | 2001-04-02 | 2004-07-15 | Julie Cahill | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2hydroxy-methylpropiono-m toluidide and pvp |
| DE10118282A1 (en) | 2001-04-12 | 2002-12-05 | Lohmann Therapie Syst Lts | Pressure sensitive adhesive based on ethylene-vinyl acetate copolymers and adhesive resins, for medical purposes |
| EP1256339B1 (en) * | 2001-05-08 | 2003-10-15 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| DE10141651B4 (en) * | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal Therapeutic System (TTS) with the active ingredient Fentanyl and process for its preparation |
| AU2002329763B2 (en) | 2001-08-17 | 2007-11-08 | Lavipharm Laboratories Inc. | Composition and transdermal drug delivery device |
| DE10159745A1 (en) | 2001-12-05 | 2003-07-03 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with improved long-term comfort |
| US6775570B2 (en) | 2002-02-04 | 2004-08-10 | Ceramatec, Inc. | Iontophoretic treatment device |
| US20030180281A1 (en) | 2002-03-11 | 2003-09-25 | Bott Richard R. | Preparations for topical skin use and treatment |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| EP1386604A1 (en) | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
| EP1386605A1 (en) | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
| DE10261696A1 (en) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
| US7603144B2 (en) | 2003-01-02 | 2009-10-13 | Cymbet Corporation | Active wireless tagging system on peel and stick substrate |
| AU2003300153A1 (en) | 2003-01-02 | 2004-07-29 | Cymbet Corporation | Solid-state battery-powered devices and manufacturing methods |
| UA81665C2 (en) | 2003-04-14 | 2008-01-25 | Лтс Ломанн Терапи-Системе Аг | Therapeutic patch with polysiloxane matrix comprising capsaicin |
| EP1663179A1 (en) * | 2003-07-21 | 2006-06-07 | Noven Pharmaceuticals, Inc. | Composition and method for controlling drug delivery from silicone adhesive blends |
| US9205062B2 (en) | 2004-03-09 | 2015-12-08 | Mylan Pharmaceuticals, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| US20050202073A1 (en) | 2004-03-09 | 2005-09-15 | Mylan Technologies, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| ES2301017T3 (en) | 2004-05-28 | 2008-06-16 | Jan De Geest | COMMUNICATION UNIT FOR THE SKIN OF A PERSON. |
| JP2006178807A (en) | 2004-12-24 | 2006-07-06 | Echigo Fudagami Kk | Apparatus and method for manufacturing ic sheet |
| GB0506139D0 (en) | 2005-03-24 | 2005-05-04 | Transphase Ltd | A transdermal topical composition and its uses |
| TWI389709B (en) | 2005-12-01 | 2013-03-21 | Novartis Ag | Transdermal therapeutic system |
| DE102006054733A1 (en) | 2006-11-21 | 2008-05-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with high drug utilization rate and dosing accuracy |
| DE102006054731B4 (en) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
| CN101147739B (en) | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | Composition containing rotigotine and its use and transdermal patch containing the composition |
| EP2178598A4 (en) | 2007-08-17 | 2012-08-15 | Isis Biopolymer Llc | Iontophoretic drug delivery system |
| EP2190430A1 (en) | 2007-08-24 | 2010-06-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of compounds derived from cycloheximide for the treatment or prevention of, in particular, ischaemias and cardiopathies |
| TW200922549A (en) | 2007-10-19 | 2009-06-01 | Abbott Gmbh & Amp Co Kg | Solid dispersion product containing N-aryl urea-based compound |
| CN102099020B (en) | 2008-05-30 | 2013-09-18 | 迈兰股份有限公司 | Stabilized transdermal drug delivery system |
| JP2009297808A (en) | 2008-06-11 | 2009-12-24 | Chiyoda Integre Co Ltd | Adhesive tape manufacturing method and adhesive tape manufacturing apparatus |
| EP2140861A1 (en) | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
| AR074047A1 (en) | 2008-09-09 | 2010-12-22 | Transcu Ltd | SYSTEMS, DEVICES, AND METHODS TO SUPPLY ENERGY TO DEVICES, FOR EXAMPLE DEVICES OF TRANSDERMAL ADMINISTRATION AND / OR TO CONTROL THEM |
| CN102281873A (en) * | 2008-10-06 | 2011-12-14 | 迈兰技术有限公司 | Amorphous rotigotine transdermal system |
| US20100286590A1 (en) | 2009-05-08 | 2010-11-11 | Isis Biopolymer Llc | Iontophoretic device with improved counterelectrode |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| DE102009052972A1 (en) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Process for preventing the crystallization of drugs in a polymer film |
| BR112013012117A8 (en) | 2010-11-23 | 2017-10-10 | Nupathe Inc | COPACKAGED SINGLE USE COPACKAGED SELF-CONTAINED IONTOPHORETIC DRUG DELIVERY SYSTEM, DRUG AND TRIPTAN COMPOUND USES |
| WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
| WO2013075822A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system (tts) with rotigotine |
| DE102012013421A1 (en) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system useful for treating, alleviating and/or preventing e.g. Parkinson's disease, depression, comprises backing layer, matrix layer comprising rotigotine, and protection film applied to part of matrix layer surface |
| DE112012005185T5 (en) | 2011-12-12 | 2014-08-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
| TW201431570A (en) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | Multi-day patch for the transdermal administration of rotigotine |
| JP6559121B2 (en) | 2013-06-04 | 2019-08-14 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal delivery system |
-
2013
- 2013-10-30 TW TW102139313A patent/TW201431570A/en unknown
- 2013-11-14 AR ARP130104186A patent/AR093481A1/en unknown
- 2013-11-21 MX MX2015006357A patent/MX354502B/en active IP Right Grant
- 2013-11-21 WO PCT/EP2013/003515 patent/WO2014079573A1/en active Application Filing
- 2013-11-21 US US14/443,210 patent/US11389410B2/en active Active
- 2013-11-21 CA CA2887085A patent/CA2887085C/en active Active
- 2013-11-21 EA EA201500553A patent/EA201500553A1/en unknown
- 2013-11-21 CN CN201380054953.XA patent/CN104736146B9/en active Active
- 2013-11-21 ES ES13795432.7T patent/ES2639294T3/en active Active
- 2013-11-21 CN CN201910246426.8A patent/CN110200950B/en active Active
- 2013-11-21 EP EP13795432.7A patent/EP2922533B1/en not_active Revoked
- 2013-11-21 AU AU2013350037A patent/AU2013350037B2/en not_active Ceased
- 2013-11-21 JP JP2015543338A patent/JP6301356B2/en active Active
- 2013-11-21 BR BR112015011729-5A patent/BR112015011729B1/en active IP Right Grant
- 2013-11-21 KR KR1020157008077A patent/KR20150094588A/en not_active Application Discontinuation
- 2013-11-21 IN IN2488DEN2015 patent/IN2015DN02488A/en unknown
-
2022
- 2022-01-31 US US17/589,262 patent/US20220151949A1/en active Pending
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999049852A1 (en) | 1998-03-30 | 1999-10-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
| WO2002015903A2 (en) | 2000-08-24 | 2002-02-28 | Schwarz Pharma Ag | Novel pharmaceutical composition for administering n-0923 |
| WO2002089777A1 (en) | 2001-05-08 | 2002-11-14 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of parkinson's disese |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| WO2003092677A1 (en) | 2002-05-06 | 2003-11-13 | Schwarz Pharma Ag | Trans-epicutaneous administration form for treating restless leg syndrome |
| WO2004012721A2 (en) | 2002-07-30 | 2004-02-12 | Schwarz Pharma Ag | Hot melt tts for administering rotigotine |
| US20040137045A1 (en) * | 2002-07-30 | 2004-07-15 | Armin Breitenbach | Hot-melt TTS for administering Rotigotine |
| EP1669063A1 (en) * | 2002-07-30 | 2006-06-14 | Schwarz Pharma Ag | Transdermal therapeutic systems for administering rotigotine |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| WO2004050083A1 (en) | 2002-12-02 | 2004-06-17 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of parkinson's disease |
| WO2005009424A1 (en) | 2003-07-26 | 2005-02-03 | Schwarz Pharma Ag | Use of rotigotine for the treatment of depression |
| WO2005063236A1 (en) | 2003-12-23 | 2005-07-14 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| WO2005063237A1 (en) | 2003-12-24 | 2005-07-14 | Schwarz Pharma Ag | Use of rotigotine for the treatment or prevention of dopaminergic neurone loss |
| WO2005092331A1 (en) | 2004-03-24 | 2005-10-06 | Schwarz Pharma Ag | Use of rotigotine for treating and preventing parkinson's plus syndrome |
| WO2009068520A2 (en) | 2007-11-28 | 2009-06-04 | Schwarz Pharma Ag | Polymorphic form of rotigotine |
| WO2011076879A1 (en) | 2009-12-22 | 2011-06-30 | Ucb Pharma Gmbh | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Non-Patent Citations (4)
| Title |
|---|
| "Clinical Phamacokinetics", 1995, WILLIAMS & WILKINS, article "Estimation of Adsorption Kinetics from Plasma Concentration Data", pages: 480 - 483 |
| "Pressure Sensitive Tack of Adhesives Using an Inverted Probe Machine", ASTM D2979-71, 1982 |
| H. F. HAMMOND; D. SATAS: "Handbook of Pressure Sensitive Adhesive Technology", 1989, VAN NOSTRAND REINHOLD, pages: 38 |
| K. L. ULMAN; R. P. SWEET: "The Correlation of Tape Properties and Rheology", 1998, INFORMATION BROCHURE, DOW CORNING CORP. |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2922533B1 (en) | 2012-11-22 | 2017-06-14 | UCB Biopharma SPRL | Multi-day patch for the transdermal administration of rotigotine |
| US11389410B2 (en) | 2012-11-22 | 2022-07-19 | Lts Lohmann Therapie-Systeme Ag | Multi-day patch for the transdermal administration of rotigotine |
| US11033723B2 (en) | 2013-07-03 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising an electronic component |
| WO2015177204A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
| WO2015177212A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| EP4238580A3 (en) * | 2014-05-20 | 2023-10-25 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system including an interface mediator |
| US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| US11426359B2 (en) | 2014-05-20 | 2022-08-30 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| US11633367B2 (en) | 2014-05-20 | 2023-04-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
| WO2016096840A1 (en) * | 2014-12-16 | 2016-06-23 | Amarin Technologies S.A. | A device for the transdermal delivery of rotigotine |
| WO2019043172A1 (en) * | 2017-09-04 | 2019-03-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an emulsifier |
| WO2019077118A1 (en) * | 2017-10-20 | 2019-04-25 | Amw Gmbh | Stabilized transdermal delivery system |
| US11648213B2 (en) | 2018-06-20 | 2023-05-16 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| RU2798017C2 (en) * | 2018-06-20 | 2023-06-14 | Лтс Ломанн Терапи-Систем Аг | Transdermal therapeutic system containing asenapine |
| WO2021148634A1 (en) * | 2020-01-24 | 2021-07-29 | Luye Pharma Switzerland Ag | Transdermal therapeutic system comprising the ingredient rotigotine and at least one non-amine-resistant silicone adhesive |
| EP3854388A1 (en) * | 2020-01-24 | 2021-07-28 | Luye Pharma Switzerland AG | Transdermal therapeutic system comprising rotigotine and at least one non-amine-resistant silicone adhesive |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016500086A (en) | 2016-01-07 |
| US20220151949A1 (en) | 2022-05-19 |
| AU2013350037B2 (en) | 2016-03-03 |
| CN110200950A (en) | 2019-09-06 |
| CN104736146B (en) | 2019-03-01 |
| EP2922533A1 (en) | 2015-09-30 |
| IN2015DN02488A (en) | 2015-09-11 |
| CA2887085A1 (en) | 2014-05-30 |
| AU2013350037A1 (en) | 2015-06-11 |
| ES2639294T3 (en) | 2017-10-26 |
| AR093481A1 (en) | 2015-06-10 |
| US11389410B2 (en) | 2022-07-19 |
| JP6301356B2 (en) | 2018-03-28 |
| CA2887085C (en) | 2020-12-22 |
| MX2015006357A (en) | 2016-02-10 |
| EA201500553A1 (en) | 2015-12-30 |
| BR112015011729A2 (en) | 2017-07-11 |
| KR20150094588A (en) | 2015-08-19 |
| EP2922533B1 (en) | 2017-06-14 |
| CN110200950B (en) | 2023-03-10 |
| US20150290142A1 (en) | 2015-10-15 |
| BR112015011729B1 (en) | 2022-08-16 |
| MX354502B (en) | 2018-03-08 |
| CN104736146A (en) | 2015-06-24 |
| TW201431570A (en) | 2014-08-16 |
| CN104736146B9 (en) | 2019-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220151949A1 (en) | Multi-Day Patch for the Transdermal Administration of Rotigotine | |
| US10130589B2 (en) | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | |
| US8246979B2 (en) | Transdermal delivery system for the administration of rotigotine | |
| US8246980B2 (en) | Transdermal delivery system | |
| EP1386605A1 (en) | Improved transdermal delivery system for the administration of rotigotine | |
| CA2490573C (en) | Improved transdermal delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13795432 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 20157008077 Country of ref document: KR Kind code of ref document: A |
|
| REEP | Request for entry into the european phase |
Ref document number: 2013795432 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013795432 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2887085 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2015543338 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14443210 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/006357 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015011729 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 2013350037 Country of ref document: AU Date of ref document: 20131121 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201500553 Country of ref document: EA |
|
| ENP | Entry into the national phase |
Ref document number: 112015011729 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150521 |